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 The steroid sulfatase (STS)-mediated desulfation is a critical metabolic mechanism that regulates 
the chemical and functional homeostasis of endogenous and exogenous molecules. In this study, 
I first showed that the hepatic expression of STS was induced in the high-fat diet (HFD) and 
ob/ob models of obesity and type 2 diabetes. Over-expression of STS in the liver of transgenic 
mice alleviated HFD and ob/ob models of obesity and type 2 diabetes, including reduced body 
weight, improved insulin sensitivity, and decreased hepatic steatosis and inflammation. 
Interestingly, STS exerted its metabolic benefit through sex-specific mechanisms. In female 
mice, STS may have increased hepatic estrogen activity and consequently improved the 
metabolic functions; whereas ovariectomy abolished this protective effect. In contrast, the 
metabolic benefit of STS in males may have been accounted for by the male-specific decrease of 
inflammation in white adipose tissue (WAT) and skeletal muscle, as well as a pattern of skeletal 
muscle gene expression that favors energy expenditure.  
 
           Chronic inflammatory liver diseases are associated with estrogen excess and feminization 
in men. The estrogen excess was reasoned to be due to liver damage that weakens the liver's 
ability to breakdown estrogen. In this study, I showed that STS may have mediated the 
inflammation induced estrogen increase in chronic liver disease. Bioinformatic and IHC analysis 
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demonstrated that STS was induced in liver samples from patients with chronic inflammatory 
liver diseases. In contrast, several enzymes involved in estrogen inactivation were down-
regulated in diseased livers, including the phase I enzymes CYP1A2 and CYP3A4 and the phase 
II enzyme estrogen sulfotransferase (EST). Mechanistically, I showed that STS is an NF-κB 
target gene, whose induction facilitates the conversion of inactive estrogen sulfates to estrogens.  
On the other hand, loss of STS or blocking estrogen signaling increased NF-κB transcriptional 
activity and inflammation. These elucidated the activation of negative feedback loop, that is, STS 
induced by NF-κB in hepatocytes enhanced estrogen activity, which in turn suppresses NF-κB-
mediated inflammation. 
 
          In summary, I have uncovered novel roles and mechanisms of STS in energy homeostasis 
and inflammation, which may facilitate the development of novel interventions for metabolic 
syndrome and chronic inflammatory liver disease.  
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1.0  CHAPTER I: AN OVERVIEW OF STS AS A STEROID-ACTIVATING ENZYME 
 
 
Aryl sulfatase C, also commonly known as STS, is a member of the sulfatase family 
which is responsible for the cleavage of sulfate esters (CO-S) and sulfamates (CN-S). STS-
mediated desulfation and sulfotransferases (SULTs)-catalyzed sulfation are reversible reactions 
that tightly regulate steroid homeostasis. The sulfation reaction usually increases the water 
solubility and decreases the bioactivity of steroids. However, rather than being readily excreted, 
steroid sulfates act as a reservoir for regenerating active steroids through the STS-mediated 
desulfation(1). STS is the only sulfatase which catalyzes the hydrolysis of steroid sulfates and 
produces unconjugated steroids in biological systems. Inactivation of STS from point mutation 
or gene deletions results in X-linked ichthyosis - due to excess deposition of cholesterol sulfate 
in the skin (2). The STS-mediated desulfation of estrogen sulfate is a major route for local 
estrogen synthesis in malignant breast tissues, which makes STS as an attractive target for 
treatment of hormone-dependent cancers(3). STS regulates the homeostasis of 
dehydroepiandrosterone (DHEA)/DHEA sulfate, which are neurosteroids regulating brain 
functions. Dysfunction of STS has been associated with ADHD(4). STS also regulates the 
steroidogenesis through increasing the translation and half-life of the steroidogenic acute 
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regulatory protein (StAR) (5). In the introduction section, I will briefly review the molecular 
biology and biological function of STS under different pathological conditions. 
 
1.1 THE STS GENE, FROM DNA TO PROTEIN 
The human STS gene is located on the short arm of the X-chromosome. It escapes X-
inactivation, a process that inactivates one X-chromosome in females to correct for the gene 
dosage differences between the genders (6). There is a pseudogene for STS on the Y-
chromosome, which is transcriptionally inactive.  The STS gene contains 10 exons spanning over 
146 kb. Alternatively spliced transcripts with different first exons were identified in different 
tissues and cell types.  However, the divergence is restricted to the N-terminal signal peptide,  
which is post-transcriptionally cleaved and thus does not change the enzymatic activity of 
STS(7-9). The 2.4 kb cDNA encodes a protein of 583 amino acids with an N-terminal 
endoplasmic reticulum-targeting signal peptide of 21-23 amino acids and potential N-
glycosylation sites which are important for protein folding and stability(10). Mutation studies 
showed that both the N-terminal and C-terminal regions are critical for the enzymatic activity of 
STS. C-terminal mutants had dominant negative effects on the activity of wild-type STS (11). 
Human STS has been purified and crystallized (12). The “mushroom-like” tertiary structure of 
STS consists of a polar spherical domain with the catalytic site facing toward the ER lumen, and 
a transmembrane domain with two antiparallel alpha helices anchoring the enzyme into the ER 
membrane. Similar to other members of the sulfatase family, STS undergoes a unique yet 
conserved post-translational modification of a cysteine residue into formylglycine (FGly) at the 
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catalytic site for the activation of enzyme activity.  This process is encoded by the sulfatase 
modifying factor 1 (SUMF1) gene (13). Mutations in the SUMF1 gene severely diminish 
catalytic activity of all sulfatases, resulting in multiple sulfatase deficiency (MSD), an autosomal 
recessive lysosomal storage disorder  (14).  The mouse Sts gene is pseudoautosomal, which is 
inherited in an autosomal pattern and escapes X-inactivation. However, there is a substantial 
divergence between mouse and human STS gene. The mouse steroid sulfatase gene spans over 9 
kb, which is much smaller than that of the human gene, and it is only around 60% identical to 
human gene at the nucleotide level and amino acid level. 
 
1.2 REGULATION OF STS AT TRANSCRIPTIONAL AND 
POSTTRANSCRIPTIONAL LEVEL 
Little is known about the regulation of STS at transcriptional level.  Characterization of 
STS promoter revealed that it resembled neither a tightly regulated gene-which contains a TATA 
box to position the RNA polymerase nor a housekeeping gene-which is usually GC rich and 
contains binding sites for SP1. On the other hand, the STS promoter is GC poor and lacks a 
TATA box and SP1 binding sites(15). Four transcription start sites were mapped over a 50bp 
region. The upstream regulatory elements contain three enhancers and one repressor region. The 
promoter activity could be detected by luciferase assay in the human placental choriocarcinoma 
JEG-3 cells, which have high STS activity. Transfection of the promoter into other cell lines, 
such as the COS-1 monkey kidney epithelial cells and cervical cancer HeLa cells did not produce 
detectable luciferase activity (15). Later, six promoters were reported to drive STS expression 
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with different first exons in various tissue and cell types. These results suggested tissue-specific 
regulation of STS transcription (16).   
 
STS expression was markedly induced in breast tumor tissues compared with normal 
tissues, which was associated with higher local estrogen levels and poor prognosis (17-19). This 
regulation may be mediated by cytokines and growth factors.  The proinflammatory cytokines 
interleukin-6 (IL-6) and tumor necrosis factor α (TNFα) increased the activity of STS in MCF-7, 
a hormone-dependent human breast cancer cell line, without affecting its mRNA expression. 
Transfection of the promoter-less cDNA of STS into the MCF-7 cells increased its activity, 
which can be further enhanced by adding IL-6 and TNFα. These data suggests that the induction 
of STS by IL-6 and TNFα in MCF-7 cells was mediated by mechanisms other than 
transcriptional regulation, such as post-translational modifications or changes in substrate 
availability (20). Insulin-like growth factor-1 (IGF-I) and basic fibroblast growth factor (bFGF) 
dose-dependently stimulated STS activity in breast cancer cell lines. The induction of STS 
activity by cytokines and growth factors may explain the increased estrogen levels in breast 
tumor tissues even in postmenopausal women who have low circulating estrogen 
concentrations(17). Interleukin-1 (IL-1) increased STS activity in MCF-7 cells. However, it 
decreased the expression and activity of STS in an IL-1 receptor-dependent manner in human 
endometrial stromal cells-suggesting cell type-specific regulation (21-22). The 
phosphatidylinositol 3-kinase/Akt pathway transduces growth factor and cytokine signals 
through phosphorylation of its substrates and promotes cell survival and tumor progression(23). 
Recently, this pathway has been reported to mediate the induction of STS expression and activity 
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by growth factors and cytokines in the PC-3 human prostate cancer cells and human 
keratinocytes (24-26).   
 
Besides cytokines and growth factors, steroid hormones have also been reported to 
induce STS at enzymatic level (27-28). Castration significantly reduced STS activity in adrenal, 
heart and liver in rats (29). On the other hand, estrogen sulfate administration enhanced the 
enzymatic activity of STS in rats-suggesting that steroid hormones induced STS through 
substrate supply (30). Stress-stimulated adrenocorticotropic hormone  (ACTH) secretion induced 
STS activity in rat adrenals (31). The ACTH-mediated secretion of adrenal steroid hormones 
(32-33) may contribute to the induction of STS in response to stress.  
 
1.3 BIOLOGICAL ROLES OF STS  
The biological roles of STS are dependent on its tissue distribution and expression, as 
well as its substrate affinity and availability. Multiple organs and tissues express STS in small 
quantities. Tissue levels of STS vary under different physiological and pathological conditions. 
STS is mainly expressed in target tissues of the reproductive tract, with the highest expression 
identified in the placenta (34-35). Placental STS plays a critical role in the formation of estriol 
from the fetoplacental unit.  Low or absent estriol levels in pregnancy were associated with STS 
deficiency and miscarriages (14). The subcellular localization of STS is mainly on the ER 
membrane, but STS has also been found in the Golgi, endosomes and plasma membranes in 
smaller fractions (10).  
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The substrates of STS are primarily steroid sulfates, such as cholesterol sulfate, 
pregnenolone sulfate, estrogen sulfates, DHEA sulfate and androsterone sulfate.  For the above 
substrates, the Km resides in the low micromolar to low nanomolar range. Sulfate metabolite of 
xenobiotics that are mimics of steroid sulfate can also enter the active site of STS and be 
efficiently hydrolyzed, such as resveratrol sulfate (36) and BPA (Bisphenol A) sulfate 
(37).  Sulfation of steroids or steroid mimics changes their polarity and bioavailability, making 
them either circulating as a reservoir for regeneration or being rapidly excreted. In addition, 
sulfation changes the structures of the molecules and affects their binding affinity or preference 
of the corresponding receptors, which further influence downstream signaling pathways in many 
physiological and pathological processes. 
 
Transport of steroid sulfates contributes to the tissue availability of STS substrate. The 
hydrophilic and charged steroid sulfates are unable to cross the lipophilic cell membranes. 
However, cell membrane transporters have been reported to uptake steroid sulfates before they 
are hydrolyzed, including the organic anion transporter (SOAT) and the organic anion 
transporting polypeptides (OATPs). SOAT specifically transports steroid sulfates in a sodium-
dependent and bi-directional manner in the adrenal gland, testes, placenta and other peripheral 
tissues; while OATP transport steroid sulfates, as well as other substrates in a sodium-
independent manner. Uptake of estrogen sulfate and DHEA sulfate by OATP was stimulated by 
prostaglandins. (38-41). 
 
The STS-mediated desulfation pathway is a major route for local estrogen synthesis. 
There are three forms of estrogen, E1 (Estrone), E2 (Estradiol) and E3 (Estriol), among which E2 
 6 
is the most active and major circulating estrogen in premenopausal women. E2 is mainly 
produced in the ovaries by aromatization of testosterone. In men and postmenopausal women, 
however, E2 is synthesized locally in extragonadal tissues such as breast, brain, bone and 
adipose tissue rather than being uptaken from the circulation (42-43).   Estrone sulfate has a 
higher concentration and longer half-life than estrone in the circulation. STS switches the 
estrogen metabolism in target cells by desulfating estrogen sulfates to active estrogens and 
promoting estrogen activity. The expression of STS was markedly induced in malignant breast 
tissues compared with normal breast tissues and was positively associated with local estrogen 
levels, tumor size, metastatic potential and poor prognosis (17-18, 44-45).  This makes STS an 
attractive target for the treatment of hormone-dependent cancers, such as breast, endometrial, 
ovarian and prostate cancer. Currently, Irosustat (STX64) is under clinical trial for treating 
endocrine-resistant breast cancer with some encouraging results (46). In addition, traditional 
Chinese herbs and food additive have been shown to inhibit the expression and activity of STS in 
vitro (47-49). Combination of STS inhibitor and other antiproliferative agents may be effective 
against hormone-dependent cancers with less drug resistance (50). 
 
Another important substrate of STS-cholesterol sulfate-is one of the most abundant 
steroid sulfates present in human circulation and also plays a critical regulatory role in the skin 
during barrier formation. Cholesterol sulfate is generated by cholesterol sulfotransferase 
(SULT2B1b) in the epidermis and is cleaved to produce free cholesterol in the outer epidermis. 
Cholesterol sulfate regulates epidermal differentiation, desquamation and barrier function(51). 
Inactivation of STS from point mutation or gene deletions results in X-linked ichthyosis, one of 
the most common human inborn errors (approximately 1 in 6000 males) of metabolism detected 
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in different ethnic groups (52-55). A 10-fold increased deposition of cholesterol sulfate due to 
loss of function of STS delays the desquamation process and results in hyperkeratosis, which is 
characterized by scaling and thickening of the skin (56-59). Accompanied with X-linked 
ichthyosis are extracutaneous manifestations including cryptorchidism, seizures, corneal opacity, 
pyloric hypertrophy, acute lymphoblastic lymphoma and abdominal wall defect (60). However, it 
is doubtful whether there is a causal relationship between the loss of function of STS and these 
clinical conditions since flanking regions of the STS gene may have also been deleted in patients 
with X-linked ichthyosis. 
 
DHEA and DHEA sulfate are primarily secreted by the adrenal cortex, but they are also 
synthesized in the central nervous system and regulate brain functions (61). DHEA sulfate act as 
gamma-aminobutyric acid A (GABAA) receptor antagonist; whereas DHEA act as GABAA 
receptor agonist. These neurosteroids also modulate the activity of N-methyl-D-aspartic acid 
(NMDA) and sigma-1 receptors (62-63).  It has been reported that circulating DHEA levels are 
inversely correlated with the symptomatology of attention deficit hyperactivity 
disorder (ADHD), a mental disorder with attention deficits, hyperactivity and impulsivity (64). 
STS-which is relatively highly expressed in both human and mouse brains-may regulate 
DHEA/DHEA sulfate levels and affect the vulnerability for developing ADHD and other 
endophenotypes. Indeed, STS dysfunction has been associated with ADHD. Human subjects 
with deletion or mutation of the STS gene are at higher risk of developing ADHD and other 
neurologic manifestations (65-66).  Polymorphism within STS has been associated with ADHD 
(67). Reduced activity of STS has been suggested to cause neural disturbances such as 
postpartum psychosis in the mothers (68). Besides human studies, genetic 
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loss or pharmacological blockade of STS gene in mice lead to attention deficits, altered 
impulsivity and increased aggressive behavior, which mimicked human ADHD (69). 
 
 BPA is a not only a widely used plasticizer, but also an endocrine disruptor through 
binding to estrogen receptor (ER). On the other hand, BPA sulfate binds poorly to the ER. 
However, BPA sulfate treatment enhanced the growth of ER-positive MCF-7 cells and free BPA 
levels inside the cells, which was due to conversion of BPA sulfate to the active BPA by the 
action of STS. Therefore, STS-mediated desulfation may increase the estrogenic potential of 
environmental estrogens (37). STS substrates also include a natural compound resveratrol, a 
naturally occurring chemopreventive agent present in grapes and wine (36). Compared with 
resveratrol, resveratrol sulfate showed poor cytotoxicity in human breast cancer cells (70). 
Differential expression of STS in malignant and non-malignant human breast tissues affected the 
sulfation metabolism of resveratrol, which dramatically lowered the bioavailability and increased 
the clearance of resveratrol. Therefore, STS may impact the therapeutic efficacy of resveratrol by 
modulating its local metabolism inside the tumors. 
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2.0  CHAPTER II: HEPATIC OVER-EXPRESSION OF STS AMELIORATES MOUSE 
MODELS OF OBESITY AND TYPE 2 DIABETES THROUGH SEX-SPECIFIC MECHANISMS  
 
2.1 ESTROGEN SIGNALING IN ENERGY HOMEOSTASIS 
 
Estrogen is not only a key reproductive steroid hormone, but it also has great implications 
in glucose and energy metabolism. Estrogen exhibits an overall protective role in preventing 
obesity and type 2 diabetes (71). Postmenopausal women face increased risk of developing 
obesity and insulin resistance. On the other hand, estrogen replacement therapies ameliorate 
metabolic disorders in both women and animal models (72-74). Estrone sulfate is the major 
active component in conjugated equine estrogens that are commonly used in hormone 
replacement therapy. Treatment with conjugated equine estrogens improved glycemic control 
and blood lipid profiles in postmenopausal, type 2 diabetic women (75). ERα knockout mice 
developed impaired insulin sensitivity and obesity (76). Mice deficient of aromatase, the enzyme 
that converts androgens to estrogens, exhibited increased adiposity and fatty liver, which were 
normalized by estrogen treatment (77-78). Human subjects lacking ERα or aromatase also 
developed insulin resistance (79-80). Despite its known metabolic benefit, a systemic treatment 
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with estrogens is limited by its potential side effects, such as increased risk for cardiovascular 
disease and tumor promotion (81).  
 
Estrogen signaling regulates energy homeostasis in both the central nervous system and 
the peripheral tissues. In the hypothalamic neurons, estrogen signaling controls food intake and 
energy expenditure, which appear to be mediated mainly by ERα. Loss of ERα in ventromedial 
hypothalamic nucleus (VMN) neurons in mice resulted in hypometabolism and obesity without 
affecting food intake. On the other hand, deletion of ERα in hypothalamic pro-opiomelanocortin 
(POMC) neurons caused hyperphagia, while the energy expenditure was not changed. These 
results indicate that estrogen signaling in distinct hypothalamic neurons regulates different 
aspects of energy homeostasis (82). In addition to the direct effects on the central nervous 
system, estrogen also regulates body weight homeostasis through the hormone leptin. Leptin is a 
catabolic hormone secreted from the WAT that reduces food intake and increases energy 
expenditure. Leptin receptors are co-localized with ERα in the brain-suggesting their close 
interactions (83). Estrogen regulates the expression of leptin receptor and enhances the 
sensitivity of leptin centrally (84-85).  
 
The liver plays an important role in lipid homeostasis by regulating the synthesis, 
catabolism and transport of lipids. The high insulin level in insulin-resistance state stimulates the 
expression of  the sterol regulatory element-binding protein 1c (SREBP-1c), a master regulator 
of hepatic lipogenesis and a mediator through which many other transcription factors 
orchestrate lipid homeostasis (86). Activation of SREBP-1c consequently regulates several rate-
limiting enzymes involved in lipogenesis, including fatty acid synthase (FAS), acetyl-CoA 
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carboxylase (ACC) and stearoyl CoA desaturase-1 (SCD-1), which contribute to increased 
hepatic lipogenesis and steatosis, and fuel the progression of insulin resistance (87). The lipid-
reducing effect of estrogen has been reported in rodents and humans. Anti-estrogen therapy in 
women resulted in abnormal lipid profile and liver steatosis (88). Aromatase knockout mice 
developed severe liver steatosis and hepatic insulin resistance (77). ERα knockout mice showed 
increased expression of lipogenic genes and decreased expression of genes for lipid transport in 
the livers (89). On the other hand, estrogen treatment reduced the expression of lipogenic genes 
and liver steatosis of HFD-fed mice in an ERα-dependent manner (90). Mechanistically, estrogen 
compromises the liver X receptor (LXR)-induced expression of SREBP-1c and triglyceride 
accumulation in an ER-dependent manner. Activated ERα directly binds to LXR and inhibits its 
coactivator recruitment on the SREBP-1c promoter-thus reducing the expression of SREBP-1c 
and lipid accumulation in the liver (91). 
 
Estrogen regulates WAT distribution and lipid metabolism. Men and women display 
different patterns of fat distribution: Men have more intra-abdominal fat, which is a risk factor of 
metabolic syndrome (92); whereas women have more subcutaneous WAT than men in general. 
Postmenopausal women and ovariectomized mice tend to have the male-patterned fat 
distribution, which can be prevented by estrogen replacement therapy (93-97). STS may also be 
participated in fat distribution through regulating estrogen homeostasis. Compared with men, E2 
levels were higher in subcutaneous WAT in women, along with higher expression of STS (98).  
ERα knockout mice and aromatase knockout mice showed adipocyte hypertrophy (76-77), while 
estrogen treatment prevented lipid accumulation in aromatase knockout mice by reducing lipid 
synthesis and uptake. Administration of estrogen to postmenopausal women and ovariectomized 
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mice reduced the expression of genes involved in lipogenesis and fatty acid uptake in adipocytes 
(99-100). In cultured adipocytes and WAT, estrogen also suppresses the expression and activity 
of lipoprotein lipase (LPL) and inhibits the breakdown of triglycerides into free fatty acids (101-
102), key mediators of insulin resistance in liver and muscle (103). In addition, estrogen 
signaling also regulates insulin sensitivity in the WAT. Estrogen activated Akt in 3T3-L1 
adipocytes in an ER-dependent manner (104). Macrophage infiltration into the WAT greatly 
contributes to obesity-induced insulin resistance (105). Ovariectomized mice displayed increased 
immune cell infiltration and expression of inflammation markers in WAT (106). Conditioned 
media from macrophages lacking ERα impaired insulin-stimulated Akt phosphorylation and 
glucose uptake in cultured adipocytes (107). These data suggest that the estrogen signaling in 
immune cells plays an important role in adipose tissue inflammation and whole-body insulin 
sensitivity.  
 
Insulin-stimulated glucose uptake mainly occurs in skeletal muscle, which is mediated by 
the glucose transporter 4 (GLUT4). GLUT4 can be activated by several different-but 
intertwined-signaling pathways, including the insulin signaling pathway, the AMP-activated 
protein kinase (AMPK) pathway and mitogen-activated protein kinases (MAPK) pathway (108-
109). Estrogen acts on key proteins involved in these pathways, which results in phosphorylation 
and activation of MAPK and AMPK (110-111) and consequent activation of GLUT4 and 
glucose disposal. Estrogen treatment also restored HFD-induced insulin resistance in mice by 
increasing the abundance of insulin receptor substrate (IRS) and phosphorylation of Akt in the 
skeleton muscle (112).  It should be noted that while ERα promotes glucose disposal and insulin 
sensitivity, ERβ may suppress GLUT4 activity and cause insulin resistance (113). More studies 
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are needed to identify the metabolic function of ERα and ERβ in the muscle. Estrogen also 
promotes insulin sensitivity in the muscle by enhancing lipid oxidation and suppressing 
inflammation. Estrogen treatment enhanced lipid oxidation in vitro and in vivo by increasing the 
expression of peroxisome proliferator-activated receptor α (PPARα) and its target genes involved 
in oxidative metabolism (114-115). On the other hand, reduction in markers of fatty acid 
oxidation, enhanced lipid content and impaired insulin sensitivity in the muscle was observed in 
ERα knockout mice (116). Accumulation of bioactive lipid intermediates can induce 
inflammation and impair insulin actions. ERα knockout mice displayed accumulation of the 
bioactive ceramides and diacylglycerol and induction of pro-inflammatory markers in the muscle 
(116). By contrast, Estrogen administration reduced neutrophil infiltration and expression of the 
inflammation marker in the skeletal muscle of ovariectomized rodents and post-menopausal 
women (117-118). 
 
β-cell failure plays a key role in the pathogenesis of type 2 diabetes. Estrogen treatment 
prevents β-cell failure in several rodent models of type 2 diabetes (119). β-cell expresses 
multiple ERs including ERα, ERβ and the G protein-coupled ER. Studies using genetic loss-of-
function approaches revealed that ERα raises glucose-stimulated insulin biosynthesis, decreases 
lipotoxicity and promotes β-cell survival; ERβ enhances glucose-stimulated insulin secretion, 
and GPER promotes insulin secretion, improves lipid homeostasis and reduces β-cell apoptosis. 
These effects may be mediated by extranuclear ERs in the β-cells (119). 
 
The estrogen homeostasis is tightly regulated by sulfation and desulfation.  Estrogens can 
be sulfated and deactivated by the EST (SULT1E1) (120). Unlike estrogen, estrogen sulfate 
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cannot bind to ER and thus are biologically inactive, but they have higher concentrations and 
prolonged half-life in the circulation, acting as a reservoir for regenerating active estrogen by the 
STS-mediated desulfation (1). It is believed that STS is the only enzyme responsible for 
desulfating estrogen sulfates. STS gene deletion or mutation caused X-linked ichthyosis, which 
is often associated with reproductive abnormalities due to disrupted steroid hormone homeostasis 
(121).  
 
It has been previously reported that EST affected mouse models of type 2 diabetes in a 
sex-specific manner (122). Loss of Est improved metabolic function in ob/ob and HFD-fed 
female mice as a result of decreased estrogen deprivation and increased estrogenic activity in the 
liver. In contrast, Est ablation in ob/ob males exacerbated the diabetic phenotype due to the loss 
of pancreatic β cells caused by increased WAT inflammation. Although STS is known to 
counteract with EST to enhance estrogen activity, whether STS can affect the pathogenesis of 
obesity and type 2 diabetes through its regulation of the estrogen homeostasis, and whether the 
effect of STS has sex specificity has not been reported.  
 
In this report, I showed that hepatic over-expression of STS elicited metabolic benefits in 
both sexes but via distinct mechanisms. The metabolic benefit in female STS mice was likely 
mediated by increased hepatic estrogen activity, whereas the protective effect of STS in males 
may have been accounted for by decreased inflammation in WAT and skeletal muscle. My 
results have uncovered a novel function of STS in regulating energy metabolism and improving 
insulin sensitivity.  
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2.2 METHODS 
2.2.1 Generation of STS transgenic mice, diet and drug treatment, body 
composition analysis, and indirect calorimetry 
 
    The human STS cDNA was cloned into the TRE-SV40 transgene cassette (123) to 
construct the TRE-STS transgene. Transgenic production was performed at University of 
Pittsburgh Transgenic Core Facility. The TRE-STS/FABP-tTA double transgenic or “STS” mice 
were generated by cross-breeding the TRE-STS mice with the FABP-tTA mice (124) and 
maintained in the C57BL/6J background.  
 
The majority of the subsequent mating was set up between the TRE-STS/FABP-tTA 
double transgenic mice and FABP-tTA single transgenic mice of the opposite sex, in which I 
observed 55.3% of female pups and 52.7% of male pups were double transgenic and expressed 
the STS transgene. These mating results suggested a Mendelian segregation of the transgene. 
The obS mice (ob/ob mice expressing the STS transgene) were generated by crossing the 
transgene into the ob/ob background. When necessary, doxycycline (DOX, 2 mg/ml) was given 
in drinking water one week before the HFD treatment and until the completion of the 
experiment. For estrone sulfate treatment, mice were treated with 75 mg/kg/day estrone-3-sulfate 
from Sigma for 5 days by oral gavage (125). HFD (Cat # S3282) with 60% of total calories 
coming from animal fat (mainly lard) was purchased from Bio-serv (Frenchtown, NJ). The HFD 
contains 37% saturated fatty acid, 47% monounsaturated fatty acid and 16% polyunsaturated 
fatty acid. Body composition by EchoMRI and indirect calorimetry by Oxymax Indirect 
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Calorimetry System were performed as previously described (126). The use of mice in this study 
has complied with relevant federal guidelines and institutional policies.  
 
2.2.2  Intraperitoneal glucose tolerance test   (IPGTT), insulin tolerance test 
(ITT), and euglycemic-hyperinsulinemic clamp 
 
    IPGTT was performed in 16-h (5:00 pm to 9:00 am) fasted mice with an 
intraperitoneal injection of D-glucose at 1g/kg body weight for ob/ob mice or at 2 g/kg body 
weight for other genotypes. ITT was performed in 6-h (9:00 am to 3:00 pm) fasted  mice with an 
intraperitoneal injection of insulin at 1.5 units/kg body weight for ob/ob mice, or at 0.5 unit/kg 
body weight for other genotypes. For euglycemic-hy-perinsulinemic clamp study, 16-h fasted 
mice were constantly infused with [3-3H] glucose at 0.05 µCi/min through a right jugular vein 
catheter at the basal state. During the clamp state, the mice were infused with a primed dose of 
human insulin from Novo Nordisk (Princeton, NJ) at 300 mU/kg body weight, followed by a 
constant insulin infusion at 2.5milliunits/kg/min. [3-3H] glucose was infused at 0.1 µCi/min. A 
variable rate of 20% glucose was infused at the same time to maintain blood glucose range 
between 120 and 140mg/dl. Blood glucose levels were monitored every 10 min. 20 µl of blood 
were sampled at the end of the basal state and clamp state for plasma [3-3H] glucose 
measurement. Liver, skeletal muscle and adipose tissue were harvested at the end of the clamp 
experiment to assess the insulin signaling (127). 
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2.2.3 Measurement of hepatic estrogen activities by liver luciferase reporter gene 
transfection 
 
    Mouse livers were transfected with the estrogen receptor responsive tk-ERE-Luc 
reporter gene by hydrodynamic injection. Hepatic luciferase activity was assessed 16 h after 
transfection and normalized to the protein concentrations (128). When necessary, ovariectomized 
and tk-ERE-Luc transfected mice were subcutaneously injected with 2.5 mg/kg estrone sulfate 6 
h after transfection. 
 
2.2.4 UPLC-MS/MS analysis of hepatic estrogens and estrogen sulfates  
 
UPLC/MS-MS were carried out with a Waters Acquity UPLC system connected with the 
Xevo TQ triple quadrupole mass spectrometer (129). The analyses were performed using Electro 
Spray Ionization (ESI) in positive ion mode, capillary voltage of 3.0 kV, extractor cone voltage 
of 3 V and detector voltage of 500 V. Desolvation gas flow was maintained at 600 L/h. Source 
temperature and desolvation temperatures were set at 150 and 350 °C, respectively. The collision 
energy was varied to optimize daughter ions. Analytical separations on the UPLC system were 
conducted using an Acquity UPLC BEH C18 1.7 µm column (1 X 50 mm) at a flow rate of 0.2 
ml/min. The gradient started with 100% A (0.1% formic acid in H2O) and 0% B (0.1% formic 
acid in CH3CN) and changed to 20% A over 5 min, then 0 % A over 2 min. Finally over 1 min it 
was changed back to original 100% A and column was equilibrated at 100% A for 2min, 
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resulting in a total separation time of 10 min. The elutions from the UPLC column were 
introduced to the mass spectrometer and resulting data were analyzed and processed using 
MassLynx 4.1 software. Reference standards were used to optimize the UPLC/MS conditions 
prior to analysis.  
 
 
2.2.5 Measurement of serum biochemistry  
 
Serum levels of estradiol (Diagnostic Systems Laboratories, Webster, TX), total 
triglycerides and cholesterol (Stanbio Laboratory, Boerne, TX), and insulin and leptin (Crystal 
Chem, Downers Grove, IL) were measured by using commercial assay kits. 
 
2.2.6 Hepatocyte glucose production assay 
 
Glucose production was measured from mouse primary hepatocytes as described before 
(130-131). Briefly, primary hepatocytes were incubated in glucose-free Dulbecco's Modified 
Essential Medium from Gibco (Grand Island, NY) containing 20 mM sodium lactate and 2 mM 
sodium pyruvate for 2 h in the presence or absence of 10 µM forskolin. Glucose production was 
measured from medium using a glucose assay kit from Sigma (St Louis, MO) and was 
normalized to protein concentrations. 
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2.2.7 Northern blotting, real-time PCR analysis, western blotting, and 
immunohistochemistry  
 
Total RNA was isolated using TRIZOL reagent from Invitrogen. Northern blot analysis 
was performed as previously described (132). 32P-labeled full-length STS cDNA was used to 
probe the transgene expression. For real-time PCR analysis, cDNA was synthesized by reverse 
transcription with random hexamer primers and Superscript RT III enzyme from Invitrogen. 
SYBR Green-based real-time PCR was performed with ABI 7300 real-time PCR system. Data 
were normalized against cyclophilin. Primary antibodies used for Western blot analysis include 
phospho-Akt (serine 473) (cat # 9271) and total Akt (cat # 9272) from Cell Signaling (Danvers, 
MA), and STS (cat# ab62219) from Abcam (Cambridge, MA). The anti-insulin antibody (cat # 
3014) used for immunohistochemistry was purchased from Cell Signaling (Danvers, MA). The 
islet area was measured using ImageJ from the National Institutes of Health (Bethesda, MD). 
 
2.2.8 Statistical analysis 
 
Results are expressed as means ± SD. Statistical significance was determined by unpaired 
two-tailed student’s t test or analysis of variance (ANOVA). The Bonferroni test was used for pot 
hoc comparisons. See Appendix A for details on statistical analyses used for each figure in the 
document. A P value less than 0.05 is considered as statistically significant.  
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2.3 RESULTS 
2.3.1 The hepatic expression of STS was induced in obese mice and by fasting, and 
the creation of transgenic mice expressing STS in the liver 
    HFD-fed mice and chow diet-fed ob/ob mice are commonly used rodent models of 
obesity and type 2 diabetes. Both models are associated with marked hepatic steatosis. In 
profiling the gene expression in HFD-fed WT mice and ob/ob mice, I found that the hepatic 
expression of endogenous mouse Sts was increased in both models (Fig. 1A). Sts was also 
induced in chow-fed mice by fasting (Fig. 1B), during which the mouse liver accumulates large 
amounts of triglycerides (133).  
 
    To understand the functional relevance of this STS induction and to investigate the 
metabolic role of STS in vivo, I created the tetracycline-responsive STS transgenic mice by 
crossing two transgenic mouse lines: the FABP-tTA line expresses the tetracycline transactivator 
(tTA) in the liver and small intestine under the fatty acid binding protein (FABP) gene promoter 
(17); and the TRE-STS line expresses STS under the control of the tetracycline response element 
(TRE). In the double transgenic mice, tTA proteins bind to TRE and initiate the expression of the 
transgenic STS; whereas administration of DOX can silence the transgene expression (Fig. 1C). 
The expression of the transgenic STS and its silencing by DOX in the liver and small intestine 
was confirmed by Northern blotting (Fig. 1D). The transgene was absent in a panel of none-
targeting tissues, including brain, kidney, skeletal muscle, brown adipose tissue, and WAT. The 
protein expression of the transgene in the liver was confirmed by Western blotting (Fig. 1E). The 
transgenic expression in the liver was also confirmed at the enzymatic level by using the tritium-
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labeled estrone sulfate as substrate (Fig. 1F). It is noted that the hepatic expression of the 
transgene was comparable between the male and female TG mice (Fig. 1G). 
 
                           
 
Figure 1. The hepatic expression of STS was induced in obese mice and by fasting and 
creation of transgenic mice expressing STS in the liver. 
A, hepatic mRNA expression of mouse Sts in chow-diet fed WT mice, HFD-fed WT mice, and ob/ob mice. B, effect 
of 16-h fasting on hepatic Sts mRNA expression in chow diet-fed WT mice. C, schematic representation of the Tet-
off STS transgenic system. FABP, fatty acid binding protein; tTA, tetracycline-controlled transactivator;SV40 
poly(A), simian virus 40 polyadenylation signal; TRE, tetracycline-response element;Pmin CMV, minimal human 
cytomegalovirus promoter. D, mRNA expression of the transgene was determined by Northern blot analysis using 
the STS cDNA as the probe. The 18 S rRNA was used as a loading control. WT, WT mice; TG, STS transgenic 
mice; LIV, liver; INT, small intestine; BAT, brown adipose tissue. E, the expression of STS protein was measured 
by Western blotting. F, the hepatic STS enzymatic activity was determined by an estrone sulfate conversion assay 
and was normalized against protein concentrations. G, the hepatic expression of STS in female and male transgenic 
mice was measured by real-time PCR. n≥4 for each group. *, p < 0.05. Error bars, S.D. 
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2.3.2 Over-expression of STS ameliorated HFD-induced obesity, insulin resistance, 
and hepatic steatosis in female mice 
      When analyzing the metabolic phenotype, I found no significant changes in body 
weight, body composition (Fig. 2A), IPGTT and ITT (Fig. 2B). However, when challenged with 
HFD, the female STS mice gained less body weight compared to their WT counterparts (Fig. 
2C). Body composition analysis showed that the reduced body weight gain in STS mice was 
mainly due to decreased fat mass, because the lean mass was comparable between the two 
genotypes (Fig. 2C). The serum level of leptin was decreased in STS mice (Table 1), consistent 
with their decreased adiposity. The body weight is maintained by balanced energy intake and 
energy expenditure. While the food intake was comparable between the two genotypes, the 
oxygen consumption and energy expenditure were significantly higher in STS mice (Fig. 2D).  
 
    Obesity is closely associated with insulin resistance. I went on to measure the insulin 
sensitivity in HFD-fed mice by IPGTT. The STS mice had lower glucose level after a 16-h fast, 
but their serum insulin level was comparable with that of the WT counterparts (Table 1), and 
they also showed improved IPGTT performance (Fig. 2E, left two panels). Interestingly, the STS 
mice and WT mice performed similarly in ITT (Fig. 2E, right two panels). The inhibition of 
hepatic glucose production by STS was recapitulated in isolated mouse primary hepatocytes, as 
the hepatocytes isolated from the STS mice showed blunted forskolin-induced glucose 
production (Fig. 2F). Hyperinsulinemic euglycemic clamp was then performed to further assess 
the effect of STS on hepatic and peripheral insulin sensitivity. The STS mice showed a 50% 
higher glucose infusion rate compared to WT mice during the clamp period (Fig. 2G, left panel), 
indicating better insulin sensitivity. The STS mice also displayed lower glucose production at 
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basal state, which may have accounted for the reduced fasting hyperglycemia. More dramatic 
suppression of hepatic glucose production in STS mice was observed during the insulin-
stimulated clamp state (Fig. 2G, right panel). To gain insight into the improved insulin sensitivity 
in STS mice, the insulin-stimulated Akt phosphorylation was measured in three major metabolic 
tissues: liver, skeletal muscle and WAT. Increased Akt phosphorylation was observed in the 
liver, but not in the skeletal muscle and WAT (Fig. 2H), suggesting a liver-specific improvement 
of insulin sensitivity. The hepatic expression of the gluconeogenic enzymes glucose-6-
phosphatase (G6pase) and phosphoenolpyruvate carboxykinase (Pepck) was suppressed in STS 
mice (Fig. 2I).  
 
    The HFD-fed STS mice also showed relief of hepatic steatosis, as evidenced by a 
reduced number and size of lipid droplets within the hepatocytes (Fig. 3A), as well as decreased 
liver triglyceride level (Fig. 3B). Interestingly, the expression of major genes responsible for 
lipogenesis (Fig. 3C) and fatty acid oxidation (Fig. 3D) was not different between WT and STS 
mice. The circulating levels of triglycerides and cholesterol were also not affected (Table 1). The 
hepatic fatty acid translocase (FAT/CD36), a fatty acid transporter responsible for the uptake of 
fatty acids from the circulation (17), was down-regulated in STS mice (Fig. 3E). Sustained liver 
steatosis is known to be associated with inflammation. Consistent with their relief of steatosis, 
the STS mice showed decreased hepatic expression of the inflammatory marker genes, such as 
the Tnfα and monocyte chemoattractant protein-1 (Mcp-1) (Fig. 3F). The suppression of 
inflammatory gene expression was liver-specific, because the expression of Tnfα and Mcp-1 was 
not affected in the WAT and skeletal muscle of the STS mice (Fig. 3F). The metabolic benefit in 
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HDF-fed female STS mice was achieved without affecting the pancreatic islet morphology and 
area (Fig. 3G). 
 
The metabolic benefit was transgene-dependent, because silencing the transgene by 
treating the STS mice with DOX normalized the body weight and body composition (Fig. 4A), 
energy expenditure (Fig. 4B), IPGTT performance (Fig. 4C), gluconeogenic gene 
expression (Fig. 4D), and inflammation marker gene expression (Fig. 4E). 
 
 
TABLE 1. Metabolic profile of HFD-fed WT and STS transgenic female mice 
 WT TG 
Serum leptin (ng/mL)  29.56±0.36 22.76 ±2.96* 
Fasting glucose  (mg/dL)  153.3±14.67 112.4±7.05* 
Fasting insulin (ng/mL) 2.1±0.52 1.69±0.36 
Serum triglyceride  (mg/dL) 104.5±7.65 99.99±4.88 
Serum total cholesterol (mg/dL) 125.1±8.21 116.8±5.06 
 
*P < 0.05. 
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Figure 2. Over-expression of STS alleviated HFD-induced obesity and improved insulin 
sensitivity.  
All mice are female. A and B, mice maintained on a chow diet were analyzed for body weight and body composition 
(A) and IPGTT and ITT (B).C–H, mice were fed with HFD for 20 weeks before analysis. C–E, body weight and 
body composition (C); food intake, oxygen consumption, and energy expenditure (D); and IPGTT and ITT (E) of 
HFD-fed mice. The quantifications of the IPGTT and ITT results are shown as the area under the curve. F, primary 
hepatocytes were measured for forskolin (FSK)-stimulated glucose production. G, glucose infusion rate (left) and 
hepatic glucose production (right).H, Western blot analysis of insulin-stimulated Akt phosphorylation in the liver, 
WAT, and skeletal muscle at the completion of euglycemic-hyperinsulinemic clamp. Arbitrary units in the bottom 
panels represent the ratio of phosphorylated Akt (p-AKT) to total Akt. I, hepatic expression of gluconeogenic 
enzyme genes was measured by real-time PCR. n≥4 for each group. *, p < 0.05.; **, p < 0.01, TG versus WT, or the 
comparisons are labeled. Error bars, S.D. 
 26 
 
Figure 3. Over-expression of STS alleviated HFD-induced hepatic steatosis and 
inflammation.  
Mice are the same as those shown in Fig. 2, C–H. A, histological analysis of liver sections by H&E staining. B, 
hepatic lipid levels. C–E, the hepatic expression of genes responsible for lipogenesis (C), fatty acid oxidation (D), 
and fatty acid uptake (E) in the liver was measured by real-time PCR. F, the expression of pro-inflammatory genes 
and/or macrophage marker genes in the liver (left), WAT (middle), and skeletal muscle (right) was measured by 
real-time PCR.G, immunostaining of insulin and quantification of total islet area. Arrowheads indicate islets. n≥4 for 
each group. *, p < 0.05, TG versus WT. Error bars, S.D. 
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Figure 4. Silencing the transgene expression abolished the metabolic benefit.  
A–E, body weight and body composition (A), energy expenditure (B), IPGTT (C), and the expression of hepatic 
gluconeogenic genes (D) and inflammation marker genes (E) in doxycycline-treated and HFD-fed female WT and 
STS mice. n≥4 for each group. Error bars, S.D. 
 
2.3.3 The metabolic benefit in female STS mice was estrogen-dependent 
    Estrogen sulfates are the preferred STS substrates existing in high concentrations in 
vivo (1, 134). Because estrogens are known for their activity in improving metabolic functions 
(71), I hypothesized that the STS transgene may have exerted its metabolic benefit by converting 
estrogen sulfates to active estrogens and enhancing estrogen signaling in the liver. Indeed, the 
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STS mice showed increased and decreased liver concentrations of estrone and estrone sulfate, 
respectively (Fig. 5A). The enhanced hepatic estrogen activity in STS mice was also supported 
by the observation that in the presence or absence of estrone sulfate treatment, the activity of an 
estrogen-responsive luciferase reporter gene tk-ERE-Luc was increased when transfected into the 
mouse liver (Fig. 5B). Despite the increased hepatic estrogen activity, neither the serum estradiol 
concentration nor the length of the estrous cycle was affected in STS mice (Fig. 5C). These 
results suggested the liver-specific increase of estrogen activity in STS mice.  
 
    To determine whether the metabolic benefit was mediated by estrogens, I eliminated 
the primary source of estrogens from 5-week-old pre-pubertal female mice by ovariectomy 
before challenging them with HFD. Ovariectomy completely abolished the metabolic benefit of 
the STS transgene in body weight and body composition (Fig. 5D), IPGTT performance (Fig. 
5E) and hepatic expression of gluconeogenic genes, inflammatory marker genes, and Cd36 (Fig. 
5F). These results suggested that the metabolic benefit in female STS mice was estrogen-
dependent.  
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 Figure 5. The metabolic benefit in female STS mice was estrogen-dependent.  
All mice are female. A, increased hepatic estrogen levels in HFD-fed female STS transgenic mice. The estrogen and 
estrogen sulfate were extracted from mouse liver and analyzed by the LC-MS method. Shown are the 
chromatographs of the estrone and estrone sulfate standards and the mouse liver extracts (left) and quantification of 
the results (right). The data were normalized against liver weight. E1, estrone; E1S, estrone sulfate. B, enhanced 
hepatic estrogen activity in female STS mice treated with vehicle (VEH) or estrogen sulfate (ES), as shown by a 
liver-specific transfection of the estrogen-responsive luciferase reporter gene tk-ERE-Luc. The data were expressed 
as the percentage of VEH-treated WT mice. C, serum estradiol levels (left) and estrus cycle length (right) were 
measured in intact mice. The length of vaginal estrus cycle was determined by vaginal smears. D–F, body weight 
and body composition (D), IPGTT (E), and the expression of hepatic gluconeogenic genes (F, left), inflammation 
markers (F, middle) and fatty acid transporter (F, right) in ovariectomized mice fed with HFD for 20 weeks. n≥4 for 
each group. *, p < 0.05, TG versus WT. Error bars, S.D. 
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2.3.4 Over-expression of STS improved metabolic function in ob/ob mice 
            The leptin-deficient ob/ob mice represent a genetic model of obesity and type 2 
diabetes. To determine the metabolic effect of STS on this model, I bred the STS transgene into 
the ob/ob background. The resulting ob/ob-STS transgenic mice were termed obS mice. Both 
ob/ob and obS mice were maintained on chow diet. Although they were not less obese, the 
female obS mice showed an improved body composition by having increased lean mass (Fig. 
6A), improved IPGTT performance (Fig. 6B), and suppression of gluconeogenic (Fig. 6C) and 
pro-inflammatory (Fig. 6D) gene expression in the liver. The obS mice also exhibited 
ameliorated liver steatosis (Fig. 6E) without affecting the expression of genes involved 
in lipogenesis and fatty acid oxidation (Fig. 6F). The serum levels of triglyceride and cholesterol 
were not affected (data not shown). The morphology and area of pancreatic islets were 
indistinguishable between the ob/ob and obS mice (Fig. 6G). These phenotypes were consistent 
with those observed in the HFD model.  
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Figure 6. Over-expression of STS improved metabolic function in ob/ob mice.  
The female ob/ob and obS mice were maintained on a chow diet. A–D, body weight and body composition (A), 
IPGTT and ITT (B), and the expression of hepatic gluconeogenic genes (C) and proinflammatory marker genes (D). 
The quantifications of the IPGTT and ITT results are shown as the area under the curve. E, histological analysis of 
liver sections by H&E staining (left) and measurement of hepatic triglyceride and cholesterol levels (right).F, 
expression of genes responsible for hepatic lipogenesis (left) and fatty acid oxidation (right), as determined by real-
time PCR.G, immunostaining of insulin and quantification of total islet area. Arrowheads, islets.  n≥4 for each 
group. *, p < 0.05, obS versus ob/ob. Error bars, S.D. 
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2.3.5 Treatment with estrogen sulfate improved insulin sensitivity in ob/ob and 
HFD models 
 
    Estrogen administration has been reported to improve insulin sensitivity in both ob/ob 
mice and HFD-fed mice (90, 135). The induction of STS in the ob/ob and HFD models (Fig. 1A) 
led to the hypothesis that administration of estrone sulfate in these models may result in the same 
estrogenic benefit-due to the increased STS-mediated conversion of estrone sulfates to estrogens 
in the liver. As shown in Fig. 7A, administration of estrone sulfate gradually reduced the fed 
glucose levels in ob/ob mice and maximized its glucose-lowering effect by day 5. The estrone 
sulfate-treated mice also showed improved IPGTT performance in both the ob/ob (Fig. 7B, top 
two panels) and HFD (Fig. 7C, left two panels) models. Interesting, the estrone sulfate treatment 
did not improve ITT performance in ob/ob mice (Fig. 7B, bottom two panels), but did so in the 
HFD model (Fig. 7C, right two panels). 
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Figure 7. Estrogen sulfate improved insulin sensitivity in ob/ob mice and HFD-fed mice.  
A and B, female ob/ob mice were maintained on a chow diet. Shown are fed glucose levels (A) and IPGTT and ITT 
(B) of vehicle (VEH) or estrone sulfate (ES)-treated ob/ob mice. C, WT female mice were fed with HFD for 16 
weeks. Shown are IPGTT and ITT of mice treated with VEH or ES. The quantifications of the IPGTT and ITT 
results are shown as the area under the curve. n≥4 for each group. *, p < 0.05, ES versus VEH. Error bars, S.D. 
 
2.3.6 Over-expression of STS improved metabolic function in HFD-fed male mice 
with distinct mechanisms 
Unlike their female counterparts, the male STS mice showed no increased activation of 
the tk-ERE-Luc reporter gene when transfected into their livers (Fig. 8A). However, the STS 
males also showed protection from the HFD challenge. Although their body weight was not 
affected, the HFD-fed STS males exhibited reduced fat mass and increased lean mass (Fig. 8B). 
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In addition, the HFD-fed STS males showed increased oxygen consumption and energy 
expenditure (Fig. 8C), improved IPGTT performance but unchanged ITT performance (Fig. 
8D), and suppression of the gluconeogenic genes and pro-inflammatory genes (Fig. 8E) in their 
livers. The HFD-fed STS males also showed inhibition of hepatic steatosis, as revealed by liver 
histology and hepatic triglyceride levels (data not shown). These results were in general 
agreement with those observed in the HFD-fed STS females. The improvement of IPGTT 
performance and inhibition of gluconeogenic gene expression (data not shown) were retained in 
HFD-fed STS males following castration, suggesting the sex hormones are dispensable for the 
metabolic benefit of STS in males.  
 
In understanding the mechanism of metabolic benefit in STS males, I found that the WAT of 
STS males showed fewer signs of inflammation, including reduced crown-like structures, and 
decreased expression of macrophage and inflammation marker genes (Fig. 8F). The inhibition of 
WAT inflammation was not seen in STS females (Fig. 3F). In addition, I observed decreased 
expression of macrophage and inflammation marker genes, increased expression of the glucose 
transporter Glut4, and increased expression of genes responsible for mitochondrial biogenesis 
and fatty acid oxidation in the skeletal muscle of STS males (Fig. 8G), which was also absent in 
STS females (Fig. 3F) (data not shown). The transgene had little effect on the area of pancreatic 
islets either in the HFD model (Fig. 8H, left panel) or the obS model (Fig. 8H, right panel).  
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 Figure 8. Over-expression of STS improved metabolic functions in male mice via distinct 
mechanisms.  
All mice are male. A, lack of change in hepatic estrogen activity in male STS mice as shown by a liver-specific 
transfection of the estrogen-responsive luciferase reporter gene tk-ERE-Luc. B–E, mice were fed with HFD for 20 
weeks before analysis. Body weight and body composition (B), oxygen consumption and energy expenditure (C), 
IPGTT and ITT (D), and expression of hepatic gluconeogenic genes (E, left) and inflammatory marker genes (E, 
right). F, H&E staining (left) and expression of macrophage and inflammatory marker genes (right) in abdomen 
adipose tissue. Arrowheads(left), crown-like structures. G, gene expression in the skeletal muscle as measured by 
real-time PCR. n≥4 for each group. H, quantification of total islet area based on insulin immunostaining. *, p < 0.05. 
Error bars, S.D. 
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2.4 DISCUSSION 
 
    This study reported the induction of hepatic STS in mouse models of obesity and 
insulin resistance, as well as during the transition from fed to fasting. The induction of STS may 
represent a protective response against metabolic stress because over-expression of STS in the 
liver improved metabolic function in both the HFD and ob/ob models of obesity and type 2 
diabetes. 
 
    The metabolic benefits of the STS transgene in female mice may have resulted from 
enhanced hepatic estrogen production as evidenced by the increased estrogen level and activity 
in the livers of STS mice, whereas ovariectomy abolished the protective effect of STS. The 
sulfation-desulfation pathways are important to maintain the local estrogen homeostasis. Under 
normal conditions, the mouse liver has a low basal expression of EST, but a substantial 
constitutive expression of STS, suggesting a dominant estrogenic activity is required to maintain 
hepatic estrogen levels and normal physiology. However, in type 2 diabetes, EST is dramatically 
and specifically induced in the liver (136), which may have increased estrogen deprivation and 
contributed to the development of insulin resistance (Fig.15). In the transgenic mice, over-
expression of STS may have regenerated active estrogens, compensated for reduced estrogen 
signaling, and thus protected mice from insulin resistance.  
 
               Although estrogens are known for their activities in preventing metabolic syndrome, 
their effector tissues or cell types remain to be clearly defined. It has been suggested that 
estrogen signaling in the central nervous system controls food intake, energy metabolism, and 
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body weight homeostasis (82). In the pancreas, estrogen actions protect β cell from death and 
promote insulin biosynthesis and secretion (119). Estrogen decreases lipogenesis and 
adipogenesis in adipose tissue, and enhances fatty acid oxidation in skeletal muscle. Estrogen 
also reduces inflammation in the muscle and adipose tissue, which altogether improves insulin 
sensitivity in these peripheral tissues (71). My results provided direct evidence that a liver-
specific enhancement of estrogen activity was sufficient to confer the metabolic benefit. The 
enhanced estrogen activity in STS mice was likely localized to the liver, because the circulating 
levels of estradiol were similar between WT and STS mice, and the increased insulin-stimulated 
Akt phosphorylation in STS mice was also liver-specific. The confinement of insulin 
sensitization to the liver may also explain why improved IPGTT performance, but not ITT 
performance, was observed in HFD-fed STS mice and chow-fed obS mice.  
 
    A systemic treatment with estrogens has been limited by their potential side 
effects (81). My results raised the promise of using liver-specific activation of estrogen signaling 
to harness the metabolic benefit of estrogens and avoid unwanted side effects. It is encouraging 
that targeted estrogen delivery has been successfully explored. In one such example, targeted 
estrogen delivery was achieved by fusing the glucagon-like peptide-1 with estrogen, which 
improved glucose and lipid metabolism without inducing endocrine toxicity and oncogenicity 
(137). In addition to direct use of estrogens, my results suggested that the delivery of the 
hormonally inactive estrogen sulfate may be a practical approach to enhance estrogen activity in 
tissues bearing a high basal or inducible expression of STS, such as the liver. 
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            Having demonstrated the sex-specific effect of Est ablation on glucose homeostasis 
(122), it was surprising to note that over-expression of STS improved glucose homeostasis in 
both male and female mice. EST is expressed in both the liver and adipose tissue. The anti-
diabetic and pro-diabetic effect of Est ablation in females and males may be due to the loss of Est 
in the liver and adipose tissue, respectively (122). In the current study, the STS transgene was 
expressed in the liver but not in the adipose tissue, which may explain the consistent benefit in 
both sexes. Interestingly, the mechanism for the protective effect of STS appeared to be sex-
specific. The protection in female mice was estrogen-dependent, but the protection in males may 
be independent of sex hormones, because the hepatic estrogen activity did not increase, and 
castration failed to abolish the protective effect in male STS mice. Instead, the metabolic benefit 
in males might have been accounted for by the male-specific inhibition of inflammation in the 
adipose tissue and skeletal muscle, as well as a pattern of skeletal muscle gene expression that 
favors energy expenditure. Another notable difference between the STS transgenic and Est null 
model is their impact on the pancreatic islets and β-cell mass. Est ablation caused a male-specific 
loss of β-cell mass in the ob/ob background, which was reasoned to be due to the WAT 
inflammation (15). In contrast, the STS transgene had little effect on the pancreatic islets either 
in the HFD model or ob/ob model regardless of the sex of the mice.       
  
           The STS transgene was not targeted to the adipose tissue and skeletal muscle, so I 
cannot exclude the possibility that the metabolic benefit of STS in these two tissues was 
secondary. Indeed, I found that the serum concentration of DHEA, which can be converted from 
DHEA sulfate by STS, was increased in male STS mice (data not shown). DHEA is known to 
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have multiple beneficial effects on the liver and extra-hepatic tissues in preventing the 
progression of metabolic syndrome (138).  
 
          The X-linked ichthyosis is resulted from inactivation of STS by complete deletion or 
point mutations (2). STS polymorphisms have been associated with vulnerability to attention-
deficit/hyperactivity disorder (65, 67). It would be interesting to know whether the 
polymorphisms of STS are associated with altered estrogen signaling and susceptibility to 
obesity and insulin resistance in human populations. In addition, several STS inhibitors are being 
developed for the treatment of breast cancer in postmenopausal women (46, 139). It is imperative 
to evaluate the effect of STS inhibitors on glucose and energy metabolism in order to avoid their 
potential side effects. 
 
             The 60 kcal% HFD I used is a widely used research diet to induce obesity and type 2 
diabetes in rodents (140). However, I understand that the 60 kcal% HFD can be toxic to non-
adipose tissues including the pancreatic beta cells (141). A future use of HFD with lower fat 
content is necessary to exclude the possibility that the toxicity of the 60 kcal% HFD may have 
impacted the phenotypic exhibition or interpretation. 
 
    In summary, the current study has uncovered a novel function of STS in regulating 
energy metabolism and improving insulin sensitivity through sex-specific mechanisms. The 
liver-specific activation of the estrogen signaling pathway was sufficient to confer metabolic 
benefit. I proposed that liver-specific STS induction or estrogen/estrogen sulfate delivery may 
represent novel approaches to manage metabolic syndrome. 
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3.0  CHAPTER III: ACTIVATION OF A NEGATIVE FEEDBACK LOOP INVOLVING 
INFLAMMATION AND STS-MEDIATED ESTROGEN HOMEOSTASIS 
 
3.1 ESTROGEN SIGNALING IN INFLAMMATION 
 
Abnormal estrogen metabolism in liver disease has been identified for decades (142). 
Concomitants of liver diseases are clinical signs and symptoms like palmar erythema, spider 
nevus(143), gynecomastia and infertility due to disturbed homeostasis of endocrine steroid 
hormones, especially estrogen. Ample studies have reported increased estrogen levels, reduced 
estrogen metabolites levels and signs of endocrine disturbance in patients with chronic liver 
disease, such as liver cirrhosis, hepatocellular carcinoma (HCC), or alcoholic liver disease. (144-
149). The hormone levels are associated with the severity of liver disease (150) while treating 
patients towards improved liver function resulted in regression of the signs of endocrine 
disturbance (151). Liver is the primary site of estrogen metabolism through the phase I oxidation 
reaction, which is mainly catalyzed by CYP1A2 and CYP3A4, and the phase II conjugation 
reaction mainly mediated by EST. It is believed that damage to the liver impairs its capacity to 
metabolize estrogen, resulting in increased estrogen levels in the circulation (152). However, 
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there are reports that changes in steroid hormone levels may occur before severe liver 
dysfunction has appeared (153). Whether the estrogen levels are increased through other 
mechanisms than pure liver damage is not known.  
 
EST and STS catalyze the sulfation-desulfation pathway of estrogen, respectively, which 
is a reversible process of metabolic conjugation and dissociation, rather than destruction of 
estrogen. The sulfation pathway, rather than the glucuronidation pathway, seemed to be 
specifically affected in chronic inflammatory liver diseases, since the level of major estrogen 
glucuronides was not changed (154).  STS gene deletion or mutation is often associated with 
reproductive manifestations, such as cryptorchidism in males and failed labor progression in 
females, which may be due to disrupted steroid hormone homeostasis (121).  STS is induced in 
malignant breast tissues compared with nonmalignant tissues(17-18, 44-45). Cytokines have 
been suggested to regulate the expression and activity of STS, although with very different 
results. IL-1 decreased the expression and activity of STS in endometrial stromal cells(21). In 
contrast, IL-6 and TNFα increased STS activity in breast cancer cells, but probably due to post-
translational mechanisms (20, 155). Therefore, little is known about the transcriptional regulation 
of STS, especially in the major estrogen-metabolizing organ: liver.  
 
The development of many chronic inflammatory liver diseases are more common in men 
than in women (156). The prognosis of female HCC patients is also much better than male 
patients (157). Although the liver is not a classic target organ of sex steroid hormones, it has 
been shown to express functional ER and regulate liver functions in response to estrogen. 
Therefore, estrogen may influence the progression from hepatitis to cirrhosis and HCC (158).   
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In this study, I provide evidence that STS is a novel target gene of nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB) which is induced in clinical liver specimens 
from patients with chronic inflammatory diseases. Using human hepatocytes, I tested the 
hypothesis that a negative feedback loop exists in which induction of STS upon NF-κB 
activation increases active estrogen levels and in turn inhibits NF-κB-mediated inflammation.  
 
3.2 METHODS 
3.2.1 Bioinformatic analysis 
The Gene Expression Omnibus (GEO) (www.ncbi.nlm.nih.gov/geo) database (159) was 
mined for STS expression in chronic inflammatory liver disease. The dataset (GSE28619) 
containing 15 samples from alcoholic hepatitis patients and 7 control liver samples were 
analyzed on Affymetrix Human Genome U133 Plus 2.0 microarrays.  
 
3.2.2 Immunohistochemical analysis, western blotting and RT-PCR analysis 
For immunohistochemistry (IHC) analysis, commercially available tissue microarray 
(TMA) slides of human liver diseases (LV1201, US Biomax, Inc., Rockville, MD) were used. 
They were provided in single core per case with clinical information of sex, age, and 
pathological diagnosis.  1 out of 30 cases of cirrhosis was excluded because of lack of 
 43 
hepatocytes. IHC staining of the TMA blocks was performed using monoclonal anti-STS 
antibody (Abcam, dilution 1:50) and heat-induced antigen-retrieval procedures. The stained 
slides were evaluated by a surgical pathologist (Y.G.) in a blinded fashion. Liver samples were 
scored according to staining intensity as weakly positive when a faint brown staining was 
detectable and as strongly positive when a dark brown staining was detectable using the l00x 
magnification. For western blot analysis, the anti-STS antibody was used with 1:200 dilution. 
For RT-PCR analysis, total RNA was isolated using TRIZOL reagent from Invitrogen. cDNA 
was synthesized by reverse transcription with random hexamer primers and Superscript RT III 
enzyme from Invitrogen. SYBR Green-based real-time PCR was performed with ABI 7300 real-
time PCR system. Data were normalized against GAPDH. 
 
3.2.3 Cell culture and drug treatment  
Human livers were obtained through the Liver Tissue Procurement and Distribution 
System, and human primary hepatocytes were isolated by three-step collagenase perfusion as 
described before (160).  Primary hepatocytes were maintained in hepatocyte maintenance 
medium from Cambrex.  The hepatoma cell line Huh7 and HEK 293 cell line were originally 
obtained from the American Type Culture Collection. Cells were maintained in Dulbecco’s 
modified Eagle’s medium (Life Technologies, Invitrogen Corp.), 10% fetal bovine serum 
(Sigma-Aldrich) and 1% penicillin-streptomycin (Life Technologies, Invitrogen) at 37 ℃. 
Chemicals used in this study include: Estrone sulfate (Cat #E0251; Sigma), estradiol sulfate (cat 
# E9505; Sigma), STX64 (cat # S1950; Sigma), Fulvestrant (ICI 182,780) (cat# I4409; Sigma), 
LPS 0111:B4 (cat # L4391; Sigma), Recombinant human TNF-alpha (cat # 210-TA; R&D 
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Systems), Phorbol 12-myristate 13-acetate (PMA) (cat# P8139, Sigma) and pyrrolidine 
dithiocarbamate (PDTC) (cat# P8765, Sigma). For PDTC treatment, cells were pretreated 
with PDTC for 30 min prior to the treatment of NF-κB activators. 
3.2.4 STS activity assay 
The hepatic STS enzymatic activity was determined from cell microsomes by an estrone 
sulfate conversion assay as described before(161). The enzyme activity was normalized against 
protein concentrations. 
3.2.5 Measurement of estrogen levels in cell culture medium  
For estrogen measurement, cells were cultured in phenol red free DMEM and dextran-
coated charcoal (DCC)-stripped FBS. Cell culture medium was removed and centrifuged at 
15,000g for 10 min. The estradiol content of the supernatant was measured by an ELISA assay 
kit (Cat # 582251; Cayman Chemicals). Estrogen concentration was normalized by cellular 
protein concentration.  
3.2.6 Plasmid construction, transient transfections, and luciferase assay  
            The 5′-regulatory sequences of human STS promoter was analyzed for potential NF-κB 
binding sites by using JASPAR matrices(162). The wild-type luciferase reporter (nt −447 to 
+150) was generated by PCR amplification using a template of human genomic DNA kindly 
provided by Dr. Jiang Li. The following primers were used for PCR: forward,  
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5’- GGGGTACCCTCTGCAGTTAGCAAACC-3’ and reverse,  
5’-GAAGATCTCTCTGTTCATGGTTTCTGCA-3’. The PCR product was digested with Kpn1 
and BglII and inserted into the same enzyme-digested pGL3-basic luciferase reporter plasmid 
(Promega, Madison, WI). The shortened luciferase reporter (nt −56 to +150) was generated using 
the following primers: forward, 5’-GGGGTACCAAAAGAATGCAGCAACTA-3’ and reverse, 
5’-GAAGATCTCTCTGTTCATGGTTTCTGCA-3’. Deletion mutants of NF-κB sites within the 
STS reporter plasmids were generated by PCR-mediated mutagenesis using the following 
primers: NF-κB-1 mutation forward, 5’-TCACCTGAAACTGAGAAAAGAATGCAGCAA-3’ 
and reverse, 5’-CTTTTCTCAGTTTCAGGTGATCCTGGTAAA-3’; NF-κB-2 mutation forward, 
5’-AGGGTTGAAAATAGATTAAACTCCCGTTCA-3’ and reverse,  
5’-TTTAATCTATTTTCAACCCTCTCTTATACCT-3’; NF-κB-3 mutation forward,  
5’-TCACCTGAAACTGAGAAAAGAATGCAGCAA-3’ and reverse,  
5’-CTTTTCTCAGTTTCAGGTGATCCTGGTAAA-3’. All mutated plasmids were confirmed 
by sequencing (model 373XL sequencer, ABI). HEK 293 cells were transfected with a luciferase 
reporter constructs and expression vectors in 48-well plates using polyethyleneimine polymer 
(kindly provided by Dr. Xiang Gao). When necessary, cells were stimulated with drugs for 24 
hours before the luciferase assay. For experiments in which estrogen and estrogen sulfate were 
added or estrogen signaling was evaluated, the cells were cultured in phenol red free DMEM and 
DCC stripped FBS. Relative reporter activity was calculated by comparing with empty vector-
transfected or vehicle-treated cells. All transfections were performed in triplicate. The human 
STS siRNA (J-009602-09) and control scrambled siRNA (D-001810-10) were purchased from 
Dharmacon Research. Transfection of siRNA was performed using DharmaFECT transfection 
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reagent 4 (Dharmacon) according to the manufacturer’s protocols. After siRNA transfection, the 
cells were collected at 24 hours for mRNA analysis, and at 48 hours for protein analysis. 
 
3.2.7 Electrophoretic mobility shift assay (EMSA) and chromatin 
immunoprecipitation (ChIP) analysis 
EMSA was performed using an in vitro translated p65 protein prepared from T7 Quick 
Coupled Transcription/Translation System (Promega) and [32P]-labeled DNA probes. The EMSA 
oligonucleotide sequences are as follows: WT NF-κB-1 forward,  
5’-CGAAACCTGGGCTTTCCAAAA-3’ and reverse, 5’-CGATTTTGGAAAGCCCAGGTT-3’; 
NF-κB-1 mutant forward, 5’- CGAAACCTTCGCTTTCC AAAA-3’ and reverse,  
5’-CGATTTTGGAAAGCGAAGGTT-3’; WT NF-κB-2 forward,  
5’- CGAGAGGGGGGAAAATCCCTTAA-3’ and reverse,  
5’-CGATTAAGGGATTTTCCCCCCTC-3’; NF-κB-2 mutant forward,  
5’-CGAGAGGGTTGAAAATAGATTAA-3’ and reverse,  
5’-CGATTAATCTATTTTCAACCCTC-3’; WT NF-κB-3 forward,  
5’-CGACACCTGAAACTCCCAAAA-3’ and reverse, 5’-CGATTTTGGGAGTTTCAGGTG-3’; 
NF-κB-3 mutant forward, 5’-CGACACCTGAAACTGAGAAAA-3’ and reverse,  
5’-CGATTTTCTCAGTTTCAGGTG-3’. The oligonucleotide was annealed and end-labeled 
with 32P. The binding reaction mixture consists of  2 μL of radioactive probe, 4 μL of p65 
protein, 1 μL of poly(dI-dC)(Cat # P4929; Sigma), 4 μL of 5*binding buffer and sterile water to 
bring the total volume up to 20 μL. For competition assay, a 200-fold excess of unlabeled 
oligonucleotide was added to the reactions. For supershift assays, the binding reaction mixture 
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was pre-incubated with 1 μL of anti-p65 antibody (D14E12; Cell Signaling Technology) for 10 
min at room temperature before adding the probe. The binding mixtures were incubated at room 
temperature for 20 min before running on 5% polyacrylamide gel in 0.5 x Tris borate-EDTA 
(TBE) at 4 ℃ for 1–3 h. The gel was dried and autoradiographed. Result of a representative 
experiment was shown.  
 
 ChIP assay was performed in Huh7 cells treated with vehicle, 50ng/mL PMA or 
40ng/mL TNFα for 6 hours. Anti-p65 antibody (D14E12; Cell Signaling Technology) or normal 
serum (IgG) was used for ChIP analysis following a two-step cross-linking method as described 
by Nowak et al.(163). The PCR primers for NF-κB binding sites within STS promoter are: NF-
κB-1 forward, 5′-CACTTGTCACTTAGCAGCA-3′ and reverse,  
5′-GACCAGGCATTTCTTTCC-3′; NF-κB-2 forward, 5′-GCCTGGTCATTGACCCAGAC-3′ 
and reverse, 5′-AGGAACAGGCCAGTGACATG-3′; NF-κB-3 forward,  
5′-GACACAAATCATACCGAAGG-3′ and reverse, 5′-GGCAGATAATGTGAGGCGGA-3′; 
IL-8 forward, 5'-CAGAGACAGCAGAGCACAC-3' and reverse,  
5'-ACGGCCAGCTTGGAAGTC-3'. 
3.2.8 Statistical analysis 
            Results are presented as means ± SD. The Student's t-test was used to 
calculate significance between two group means. Analysis of variance (ANOVA) was used to 
calculate significance between multiple group means (see Appendix A for details). Fisher’s exact 
test was used to calculate statistical significance for categorical data. For correlation analysis, 
mRNA expression data were log-transformed and analyzed by Spearman rank correlation. P < 
0.05 was considered as statistically significant.  
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3.3 RESULTS 
3.3.1 Induction of STS expression is frequent in chronic liver disease 
A search of the GEO database revealed that STS was up-regulated in patients with 
alcoholic hepatitis (GSE28619)(164), (Fig. 9A). Concomitant of STS induction was the 
reduction of phase I and phase II enzymes involved in estrogen metabolism: CYP1A2, CYP3A4 
and EST (Fig. 9B), which supports the clinical observation of impaired estrogen inactivation in 
liver disease(152). Further analysis revealed significant inverse correlations between the mRNA 
expression of STS and CYP1A2 (Spearman R = -0.6894; P = 0.0004), CYP3A4 (Spearman R = -
0.6940; P = 0.0003) and EST (Spearman R = -0.7741; P < 0.0001). The activated estrogen 
formation pathway and suppressed estrogen elimination pathway may together increase estrogen 
level and bioactivity during the progression of alcoholic hepatitis. On the other hand, the 
expression of Interleukin-8 (IL-8) was up-regulated in hepatitis livers (Fig. 9C). IL-8, an NF-κB 
target gene, has been shown to be strongly activated in patients with chronic liver diseases and 
correlated with liver function and hepatic macrophages accumulation(165). The positive 
correlation between the mRNA expression of STS and IL-8 (Fig. 9D) suggests a possible 
association between inflammation and STS.  
 
To validate the microarray data, I performed an IHC staining of STS expression in a 
TMA of control and cirrhosis liver specimens (Fig. 9E). IHC analysis showed a homogeneous 
cytoplasmic staining pattern in STS stained hepatocytes. The negative control in which the 
primary antibody was omitted did not reveal any detectable staining-suggesting the staining was 
STS-specific. I categorized patient samples into weak or strong staining groups according to the 
 49 
immunoreactivity of STS. Fig. 9E depicted representative examples of weak and strong staining 
intensity. Of the 29 cirrhosis samples examined, 22 (75.86%) showed strong staining for STS 
and 7 (24.14%) showed weak staining. Analysis of the association between STS expression and 
clinicopathological factors among the 43 patients revealed that the presence of cirrhosis was 
strongly associated with STS expression (Table 2) (P =0.018), while the staining intensity of 
STS did not correlate with gender or age (Table 2). In summary, the induction of the STS gene 
expression is a very common event in chronic inflammatory liver disease.  
 
Figure 9. STS was induced in patients with chronic inflammatory liver diseases.  
A to C, mRNA expression of human STS (A), CYP3A4, CYP1A2 and EST (B) and IL-8 (C) in patients with 
alcoholic hepatitis (GSE28619). D, correlation between the expression of IL-8 and STS in control and alcoholic 
hepatitis patients. E, IHC analysis of TMA of liver cirrhosis representing different STS expression. The top two 
panels are representative cases showing weak and strong expression of STS in cirrhosis patients. The bottom two 
panels are their corresponding controls without primary anti-STS antibody. *, p≤0.05; **, p≤0.01; ***, p≤0.001, 
control versus alcoholic hepatitis group. 
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 TABLE 2. Immunohistochemical expression of STS in cirrhosis patients and controls in 
relation to clinicopathologic features 
 
   
STS  
 Variable Categorization n  %  Weak  Strong  P-value 
Age 
(years) 
     
0.215 
 
≤50  21 48.84 10 11 
 
 
>50  22 51.16 6 16 
 Gender 
     
0.304 
 
Female 11 25.58 6 5 
 
 
Male 32 74.42 10 22 
 Cirrhosis  
     
0.018* 
 
Absence 14 32.56 9 5 
 
 
Presence 29 67.44 7 22 
  
A statistical analysis was conducted with two-sided Fisher's exact test for all the parameters. *P 
<0.05.  
 
3.3.2 Activation of NF-κB induced STS expression and activity in human 
hepatocytes  
The NF-κB family of transcription factors modulates various aspects of the inflammatory 
responses, and chronic NF-κB activity has been implicated in several liver diseases including 
hepatitis, liver fibrosis, cirrhosis and hepatocellular carcinoma(166).  To test the effect of NF-κB 
activation on the expression of STS, I treated human primary hepatocytes with LPS, which 
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signals through toll-like receptors (TLRs) to stimulate NF-κB. LPS increased STS mRNA 
expression as determined by real-time PCR analysis (Fig. 10A). The induction of STS seemed to 
be human-specific because LPS had little effect on hepatic expression of mouse Sts (Fig. 10B). 
Despite the induction of STS, the expression of estrogen-deactivating enzymes was down-
regulated upon LPS treatment, including CYP3A4, CYP1A2 and EST (Fig. 10C), which was 
consistent with the in vivo data. Consistent with increased mRNA level of STS gene, the protein 
expression (Fig. 10D) and enzymatic activity (Fig. 10E) of STS were also induced by LPS in 
human primary hepatocytes. To investigate whether activation of NF-κB is necessary for STS 
induction, I analyzed the induction of STS in the presence of a selective NF-κB inhibitor 
PDTC.  As shown in Fig. 10D, pretreatment with PDTC abolished the induction of STS by LPS. 
These results support that STS expression is dependent on NF-κB signaling pathway. Besides the 
human primary hepatocytes, I also used the hepatic cell line Huh7 as another in vitro model to 
study the effect of NF-κB activation on the expression of STS. NF-κB activators TNF-α and 
PMA act through TNF receptor (167) and protein kinase C (168) to stimulate NF-κB activity, 
respectively. The same as in human primary hepatocytes, I also observed the induction of STS 
gene at mRNA and protein levels in an NF-κB-dependent manner (Fig. 10 F and G).  
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Figure 10. Induction of STS in human hepatocytes through the NF-κB signaling pathway.  
A, mRNA expression of STS in human primary hepatocytes (HPH) treated with vehicle (VEH) or LPS (1μg/ml) for 
24 hours. B, hepatic mouse Sts expression in CD-1 mice treated with either vehicle (VEH) or LPS (5 mg/kg) for 16h. 
N=3 for each group. C, mRNA expression of CYP3A4, CYP1A2 and EST in VEH- or LPS (1μg/ml) -treated HPH. 
D, protein expression of STS in HPH treated with VEH, LPS, or LPS plus PDTC (50 μM) for 24 hours. E, 
enzymatic activity of STS in HPH treated with VEH or LPS. F and G, mRNA expression (F) and protein expression 
(G, top panel) of STS in huh7 cells treated with vehicle, PMA (50ng/mL) or TNFα (40ng/mL) for 24 hours. Effect 
of PDTC on PMA- or TNFα-induced STS expression in huh7 cells (G, bottom panel). *, p≤0.05; **, p≤0.01 
compared with the vehicle group. 
 
3.3.3 STS is an NF-κB target gene 
Sequence inspection of the 5'-flanking region of the STS gene revealed three potential 
NF-κB binding motifs located between nucleotides -50 and -500 (Fig. 11A). EMSA was used to 
assess the ability of these binding sites to form complexes with p65 protein, a major subunit of 
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NF-κB transcription complex (Fig. 11B). I made STS probes containing individual NF-κB 
binding site as well as their corresponding mutants. The WT probes formed protein-DNA 
complexes with p65 and showed mobility similar to that of the complex formed with the κB site. 
The positive control κB site is derived from the MHC class II-associated invariant chain 
gene(169). Mutations of the putative NF-κB binding site attenuated or eliminated the p65 
binding, suggesting site-specific binding. The binding specificity was further confirmed by 
competition experiments, in which excess amounts of unlabeled WT probes, but not mutant 
probes, out-competed the p65 binding with the labeled WT probes. The p65 antibody was 
included to the binding reaction to identify the protein bound to STS probes, which decreased the 
mobility of the protein-DNA complex with a supershift. All three NF-κB binding sites within 
STS promoter can specifically bind to p65 protein, with nucleotides -279/-270 showing the 
strongest binding affinity and nucleotides -66/-57 showing the weakest binding affinity. To 
examine whether the NF-κB-binding motifs within the STS promoter are transcriptional active, I 
linked the WT, mutant and shortened STS promoters to the luciferase gene. These resulting 
luciferase reporters were transfected into human HEK293 cells (Fig. 11C). Co-transfection of 
p65 induced the luciferase gene expression driven by WT STS promoters. On the other hand, 
elimination or mutation the NF-κB binding sites markedly attenuated or abolished the p65-
induced luciferase activity. Consistent with the EMSA result, the most proximal site at -66/-57 
showed weakest basal and p65-induced luciferase activity.  I assessed the in situ binding of p65 
by using ChIP assay performed on chromatin isolated from TNFα-stimulated Huh7 cells. The 
p65 protein showed association with all three putative binding sites within the STS promoter 
after stimulation, as with the classical NF-κB target gene IL-8 (Fig. 11D).  
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 Figure 11. STS is a transcriptional target of NF-κB.  
A, Schematic diagram of the 5'-flanking region of STS gene. Note the presence of three NF-κB binding sites. B, 
EMSA of NF-κB binding sites derived from the human STS promoter. C, Analysis of STS promoter activity by 
luciferase reporter assay performed in HEK293 cells. Results are fold induction over the luciferase activity of the 
empty vector pGL-3 and represent means ± SD from triplicate assays. D, ChIP assay performed with Huh7 cells 
using anti-p65 antibody or normal serum (IgG), with the primers amplifying different regions of the STS promoter. 
IL-8 promoter region was included as a positive control. *, p≤0.05; **, p≤0.01 compared with the vehicle or vector 
group. 
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3.3.4 Activation of a negative feedback loop involving STS and NF-κB 
Estrogen sulfates are the preferred STS substrates existing in high concentrations in vivo 
(1, 134). I hypothesized that the induction of STS by NF-κB activators may convert estrogen 
sulfates to active estrogens and enhance estrogen signaling in the hepatic cells. Indeed, PMA 
treatment increased the estrogen levels in cell culture supernatants from Huh7 cells, which were 
abolished by knocking down STS (Fig. 12A).  The knockdown efficiency of STS was shown at 
both mRNA and protein levels (Fig. 12B). The estrogen may be converted from serum estrogen 
sulfate since the “estrogen free” DCC stripped FBS used for cell culture contains relatively high 
level of estrogen sulfate (data not shown) despite very low level of estrogen.  Consistent with 
increased estrogen levels, the estrogen activity, as demonstrated by the estrogen-responsive 
luciferase reporter gene, was also enhanced by PMA treatment. Adding estrogen sulfate, the STS 
substrate, further enhanced the PMA-induced luciferase activity (Fig. 12C). The induction of 
estrogen activity was dependent on NF-κB, because pretreatment with PDTC blocked the PMA 
induced luciferase activity (Fig. 12D). In addition, the STS inhibitor STX64 or the ER antagonist 
ICI significantly attenuated or abolished the PMA-induced ERE-luciferase activity, suggesting 
that the NF-κB induced estrogen activity was mediated by STS (Fig. 12D). Consistently, the 
expression of estrogen-responsive genes was induced by NF-κB activation in an STS-dependent 
manner (Fig. 12E and F). 
 
Given the well-known anti-inflammatory activities of estrogen (170), I hypothesized that 
the induction of STS in response to NF-κB activation may serve to terminate the NF-κB response 
through the estrogen signaling pathways. The PMA-induced transcriptional activation of NF-κB 
was blocked by estrogen as determined by the NF-κB-responsive luciferase activity (Fig. 13A). 
 56 
Estrogen sulfate also moderately reduced the NF-κB-luciferase activity-probably due to its 
conversion into estrogen by endogenous STS (Fig. 13A). Indeed, after co-transfection of the STS 
expression vector, the NF-κB activity was comparable between the estrogen sulfate group and 
the estrogen treatment group (Fig. 13A). On the other hand, the STS inhibitor STX64 or the 
estrogen receptor antagonist ICI further enhanced the PMA-induced NF-κB luciferase activity 
(Fig. 13B), as well as the expression the NF-κB target genes (Fig. 13C and E). Besides the 
pharmacological inhibitor, I also used the siRNA to knockdown STS gene. Consistently, 
knocking down of STS also enhanced the expression of NF-κB target genes (Fig. 13. D). These 
results suggest that the STS-mediated estrogen signaling suppressed NF-κB activity and 
inflammation in hepatocytes. 
   
Figure 12. Activation of NF-κB enhanced estrogen activity in human hepatocytes. 
A, E2 levels in cell culture supernatant from control siRNA or siSTS-transfected Huh7 cells treated with either 
vehicle(VEH)- or PMA (50ng/mL) for 24 hours. B, knock-down efficiency of siSTS as determined at mRNA level 
(left panel) by RT-PCR analysis and protein level (right panel) by western blotting. C, ERE-luciferase activity in 
Huh7 cells treated with VEH, PMA, 1μM estrone sulfate (ES) or both PMA and ES. D, Effect of 25 μM PDTC, 10 
μM STX64 or 100 nM ICI on PMA-induced ERE-luciferase activity. E, Effect of LPS (1μg/mL) on the expression 
of estrogen-responsive genes in human primary hepatocytes. F, Effect of TNFα (40ng/mL) on the expression of 
estrogen-responsive genes in Huh7 cells transfected with control siRNA or siSTS. *, p≤0.05; **, p≤0.01; ***, 
p≤0.001 compared with the vehicle group, or the comparisons are labeled. 
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Figure 13. STS-mediated estrogen signaling suppressed NF-κB activity.  
A, treatment of 100nM estrone sulfate (ES) or 10nM estradiol (E2) attenuated the PMA (50ng/mL)-induced NF-κB 
transcriptional activity in Huh7 cells transfected with empty vector or STS expression vector. B, effect of 10 μM 
STX64 or 100 nM ICI on PMA-induced NF-κB luciferase activity. Effect of blocking STS by pharmacological 
inhibitor STX64 (C) or genetic knockdown (D) on TNFα (40ng/mL)-induced expression of NF-κB target genes. E, 
effect of ICI on the expression of NF-κB target genes induced by TNFα. *, p≤0.05; **, p≤0.01 compared with the 
vehicle group, or the comparisons are labeled. 
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3.4 DISCUSSION 
 
Chronic inflammatory liver diseases are commonly associated with estrogen excess. The 
conventional hypothesis is that liver damage reduces the liver's ability to inactivate the estrogen. 
My study first suggested that the increased expression and activity of STS during inflammation 
may have contributed to the altered estrogen metabolism during chronic liver diseases. In 
contrast to the induction of STS, several of the estrogen-metabolizing enzymes was down-
regulated in diseased livers, including CYP1A2, CYP3A4 and EST. CYP1A2 and CYP3A4 
catalyze the phase I metabolism of estrogen and generate 2-hydroxy metabolites in human livers. 
The reduction of CYP1A2 and CYP3A4 is consistent with the previous report of reduced 
expression of estrogen-metabolizing enzymes in liver disease (171), and a significant impairment 
of 2-hydroxy estrogen metabolites in cirrhosis patients(172). Mechanistically, the expression of 
these estrogen metabolizing genes has been subjected to transcriptional and post-transcriptional 
regulations mediated by several transcription factors and kinases (173). Therefore, the decreased 
elimination and increased formation of active estrogen may together increase estrogen level and 
bioactivity during chronic inflammatory liver diseases (Fig. 15). 
 
The STS expression was also significantly correlated with the expression of IL-8, a major 
pro-inflammatory cytokine and NF-κB target gene, suggesting a possible association between 
STS and NF-κB signaling. I, therefore, examined the effect of NF-κB activation on hepatocytes 
and found an NF-κB-dependent upregulation of the STS gene at mRNA, protein and enzyme 
levels. Furthermore, NF-κB-induced STS is functional in catalyzing the conversion of estrogen 
sulfate to estrogen as evidenced by the NF-κB- and STS-dependent increase in estrogen level and 
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activity. Since STS is expressed in many tissues and cell types, I cannot exclude the possibility 
that STS in extra-hepatic tissues and cells may also contribute to estrogen increase in 
inflammatory liver diseases. The induction of STS seemed to be human-specific because LPS 
treatment did not affect the mouse Sts expression in the liver. This result may be due to the 
substantial divergence between mouse Sts and human STS gene: The mouse Sts gene spans over 
9 kb, which is much smaller than human STS, and it is only around 60% identical to human STS 
at the nucleotide level and amino acid level. This result may suggest the gap between mouse 
models and human disease. However, further studies using mouse models of chronic liver 
diseases are needed to validate this result.  
 
Previous characterization of human STS promoter revealed that it resembled neither a 
tightly regulated gene-which contains a TATA box to position the RNA polymerase; nor a 
housekeeping gene-which is usually GC rich and contains binding sites for Sp1. On the other 
hand, the STS promoter is GC poor and lacks the TATA box and Sp1 binding sites(15). Here I 
identified novel regulatory element in the human STS promoter which is critical for NF-κB 
induced gene expression in hepatocytes. The DNA element is composed of three closely 
positioned putative NF-κB binding sites: site 1 (-429 to -420), site 2(-279 to -270) and site 3(-66 
to -57). EMSA, luciferase and ChIP data revealed that site 1 and site 2 better resembled the 
canonical NF-κB binding site and contributed to the NF-κB induced expression of the STS gene 
than did site 3. However, all three sites may be required for maximal promoter activity since 
mutation of all three binding sites most profoundly compromised both the basal and inducible 
promoter activity. These results suggest that the activation of the STS gene may require more 
than one NF-κB binding site. 
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 STS is likely to play a protective role against NF-κB-mediated inflammation, because 
loss of STS by pharmacological inhibition or genetic knockdown increased NF-κB 
transcriptional activation and its target gene expression. The beneficial role of STS may be due 
to increased estrogen level and activity, since blocking estrogen receptor achieved the same 
effects in enhancing NF-κB transcriptional activity as did inhibition of STS. The NF-κB family 
of transcription factors modulates various aspects of the inflammatory responses, and chronic 
NF-κB activity has been implicated in several liver diseases including hepatitis, liver fibrosis, 
liver cirrhosis and HCC(166). In the canonical NF-κB pathway, the extracellular stimulators 
activate the IκB kinase (IKK) complex. The IKK complex phosphorylates and degrades the 
inhibitors of NF-κB (IkBs), thus frees the NF-κB complex from IκBs in the cytoplasm. Activated 
NF-κB is translocated to the nucleus, binds to promoters of target gene and recruits coactivators 
to promote gene transcription. ER has been shown to inhibit NF-κB activity at almost each, and 
every step mentioned above, including (a) Blocking IKK activity; (b) Inhibiting IκB degradation; 
(c) Hindering DNA binding by NF-κB; (d) Competing with NF-κB for coactivator binding, and 
(e) Inhibiting NF-κB-mediated transcriptional activation by binding directly to DNA-bound NF-
κB (174). It should be noted that the NF-κB activation-mediated inflammation in hepatocytes 
plays a dual role in the pathogenic progression of liver diseases. In early stages of liver diseases, 
NF-κB prevents hepatocytes cell death by inducing antiapoptotic genes. In late stages, however, 
NF-κB also promotes the survival of hepatocytes harboring oncogenic mutations-a major source 
of HCC (166). Future studies are required to clarify the function of STS-mediated estrogen 
increase in acute versus chronic inflammatory liver diseases. Despite its known anti-
inflammation effect, a systemic treatment with estrogen may cause feminization in men. Given 
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the inducibility of STS expression during inflammation, targeted delivery of the hormonally 
inactive estrogen sulfate may avoid the unwanted side effects while maintaining the benefits of 
estrogen.  
 
In conclusion, my results provided a new endocrine basis for the estrogen increase in 
chronic liver diseases, and confirmed the presence of negative feedback loop that is triggered by 
initial activation of NF-κB, which induces STS expression in hepatocytes and converts inactive 
estrogen sulfate metabolites into active estrogens. The resulting estrogens may inhibit NF-κB-
mediated inflammation via the ER signaling, thereby completing the negative feedback loop 
(Fig. 14). These findings indicate the critical role of the hepatic microenvironment in regulating 
estrogen activity, and identify STS-mediated bidirectional interaction between the estrogen 
signaling and inflammatory response. 
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Figure 14. Reciprocal regulation between inflammation and STS-mediated estrogen 
signaling. 
During chronic inflammation, activated macrophages release proinflammatory cytokines such as TNFα, IL-6 and 
IL-1, which act on neighboring hepatocytes to elicit NF-κB activation. NF-κB induces the expression of STS, which 
converts inactive estrogen sulfate to active estrogen and increases estrogen level in the circulation.  On the other 
hand, activation of estrogen signaling by STS may suppress the NF-κB response and inhibit inflammation. 
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4.0  CHAPTER IV: SUMMARY AND PERSPECTIVES 
The research goal of this dissertation is to elucidate the role of the STS-mediated estrogen 
homeostasis in energy metabolism and inflammation. Estrogen is not only a key hormone in 
reproduction, but it also has great implications in glucose and energy metabolism. Estrogens 
exhibit an overall protective role in preventing obesity and type 2 diabetes. Estrogen homeostasis 
is tightly regulated by sulfation and desulfation.  The STS-mediated desulfation is a critical 
metabolic mechanism that regulates the chemical and functional homeostasis of estrogen. Here I 
showed that over-expression of STS in the liver of transgenic mice alleviated HFD and ob/ob 
models of obesity and type 2 diabetes, including reduced body weight, improved insulin 
sensitivity, and decreased hepatic steatosis and inflammation. Interestingly, STS exerted its 
metabolic benefit through sex-specific mechanisms. In female mice, hepatic over-expression of 
STS elicited liver-specific increase of estrogen activity and improvement of the metabolic 
functions; whereas ovariectomy abolished this protective effect (Fig. 15). In contrast, the STS 
males displayed extra-hepatic metabolic benefits, including the male-specific decrease of 
inflammation in WAT and skeletal muscle, as well as a pattern of skeletal muscle gene 
expression that favors energy expenditure. My results have uncovered a novel function of STS in 
energy and glucose metabolism. Liver-specific STS induction or estrogen/estrogen sulfate 
delivery may represent a novel approach to manage metabolic syndrome. 
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The decreased body weight and adiposity in STS females may have resulted from their 
enhanced energy expenditure.  The STS transgene was not expressed in the brain, which 
modulates energy expenditure. Therefore, certain metabolic information from the transgenic 
livers may affect the brain via humoral or the neuronal pathway. In STS females, the increased 
estrogen activity was likely localized to the liver because the circulating estradiol levels were 
similar between WT and STS mice. Thus, it may be the neuronal pathway that mediates the 
liver-to-brain communication. Neuronal pathway from the liver has been reported to regulate 
energy expenditure and insulin sensitivity (175). However, how hepatic STS affects autonomic 
afferents in transmitting metabolic information to the brain, and whether estrogen or other 
mediators are involved in this process are remained to be studied.  
 
The phenotype of STS males is rather intriguing. Since the STS transgene was not 
targeted to the adipose tissue and skeletal muscle, it is likely that the transgenic liver releases 
protective mediators to benefit extra-hepatic tissues. Serum profile analysis showed that serum 
DHEA, which can be converted from DHEA sulfate by STS, was increased in STS males. STS 
mutant mice were reported to have decreased serum DHEA levels(176). Polymorphism of STS 
(SNP accession no. rs_13648) was associated with plasma DHEA and DHEA sulfate 
concentrations and body composition in response to exercise. Individuals with the more DHEA-
responsive G allele had greater fat mass loss than individuals with a common A allele only(177). 
DHEA has multiple beneficial effects during the progression of metabolic syndrome, including 
increasing lean body mass, reducing fat mass, lowering inflammation and improving insulin 
sensitivity (178-182), which phenocopied the metabolic benefits observed in STS males. It might 
be possible that the enhanced circulating DHEA in male STS mice contributed to the systemic 
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protection. However, whether and why the elevation of circulating DHEA followed a male-
specific pattern require further studies. In the future, transgenic mice with adipose tissue- or 
skeletal muscle-specific over-expression of STS, which have been developing in our lab, can be 
used directly to study the local metabolic function of STS. These genetic models will serve to 
dissect the metabolic function of STS-mediated steroid homeostasis in different tissue or cell 
types. 
 
 
 
Figure 15. Schematic illustration of the role of the STS-mediated estrogen homeostasis in 
energy homeostasis and inflammation.  
Under physiological conditions, estrogen homeostasis is maintained by the balanced sulfation and desulfation 
reactions catalyzed by EST and STS. However, in mouse models of type 2 diabetes, EST is dramatically induced in 
the liver, which overrides the small increase of STS, resulting in increased estrogen deprivation and contributing to 
the development of insulin resistance. During chronic inflammation, activation of NF-κB induces the expression of 
STS. On the other hand, EST was down-regulated, which together increase estrogen level and bioactivity in the 
circulation. STS-mediated activation of estrogen signaling may suppress the NF-κB response and inhibit 
inflammation. 
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Abnormal estrogen metabolism in liver disease has been identified for decades. 
Concomitants of liver diseases are clinical signs and symptoms indicating estrogen excess. Liver 
is the primary site of estrogen metabolism through phase I oxidation and phase II conjugation 
reactions. The estrogen excess was reasoned to be due to liver damage that weakens the liver's 
capacity to breakdown estrogen. Estrogen may participate in the progression of chronic liver 
diseases. The developments of many chronic inflammatory liver diseases are more common in 
men than in women. The prognosis of female HCC patients is also much better than male 
patients. In this dissertation study, I showed that STS may mediate the inflammation induced 
estrogen increase in chronic liver disease. Bioinformatic and IHC analysis demonstrated that 
STS was induced in liver samples from patients with chronic liver diseases, such as hepatitis and 
cirrhosis, despite of down-regulation of several enzymes involved in estrogen inactivation. 
EMSA, luciferase assay and ChIP analysis revealed that STS is an NF-κB target gene, whose 
induction facilitates the conversion of inactive estrogen sulfates to estrogens. On the other hand, 
loss of STS or blocking estrogen signaling increased NF-κB transcriptional activity and 
inflammation (Fig. 15). These studies define a novel mechanism of estrogen increase during 
inflammatory liver disease and identify STS as a mechanistic linker between estrogen action and 
inflammatory response. 
 
Although blocking STS-mediated estrogen signaling increased NF-κB transcriptional 
activity and inflammation at cellular level, the in vivo role of estrogen increase in liver disease is 
unclear. Liver disease induced estrogen excess is usually considered harmless and often 
reversible as liver function improves. However, whether the estrogen increase merely serves as a 
marker of liver dysfunction or it may affect liver function, and the progression of chronic liver 
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disease is not known. Moreover, NF-κB activation represents a double-edged sword in the 
pathogenic progression of liver diseases. Although chronic activation of NF-κB-mediated 
inflammatory response promotes the development HCC, activation of NF-κB in early stages of 
liver disease also fights against infection and prevents hepatocyte cell death. Therefore, future 
studies are needed to identify the point when NF-κB activation becomes oncogenic, so that more 
precise treatment can be launched. Systemic estrogen treatment is limited by potentially adverse 
effects such as tumor promotion and risk of cardiovascular disease. Estrogen may also cause 
feminization and other adverse effects in males, the majority of HCC cases. In addition, estrogen 
administration to patients with liver disease may enhance the workload of the already 
embarrassed liver. Therefore, it requires rigorous validation before using estrogen-related 
therapy in the treatment of chronic liver disease. 
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 APPENDIX A  
STATISTICS 
Figure 1, panel A. One-way analysis of variance. P<0.05. Bonferroni's multiple comparison test. 
WT-chow vs WT-HFD, P<0.05. WT-chow vs ob/ob, P<0.05. 
Figure 1, panel B. Student’s t-test. Two tailed. Fed vs Fasting, P<0.05. 
Figure 1, panel F. One-way analysis of variance. P<0.05. Bonferroni's multiple comparison test. 
WT-VEHICLE vs TG-VEHICLE, P<0.05. WT-DOX vs TG-DOX, P>0.05. 
Figure 1, panel G. Student’s t-test. Two tailed. Male TG vs Female TG, P>0.05. 
Table 1. Two-way analysis of variance. WT vs TG. P<0.05. Bonferroni posttests. Serum leptin, 
P<0.05. Fasting glucose, P<0.05. Fasting insulin, P>0.05. Serum triglyceride, P>0.05. Serum 
total cholesterol, P>0.05. 
Figure 2, panel A. Two-way analysis of variance. WT vs TG. P>0.05.  
Figure 2, panel B, IPGTT. Two-way repeated measures analysis of variance, WT vs TG. P>0.05. 
Student’s t-test, two tailed, WT-AUC vs TG-AUC, P>0.05. ITT. Two-way repeated measures 
analysis of variance, WT vs TG. P>0.05. Student’s t-test, two tailed, WT-AUC vs TG-AUC, 
P>0.05. 
Figure 2, panel C. Two-way analysis of variance. WT vs TG. P<0.05. Bonferroni posttests. Body 
weight, P<0.05. Lean mass, P>0.05. Fat mass, P<0.05.  
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Figure 2, panel D. Food intake. Student’s t-test. Two tailed. WT vs TG. P>0.05. Oxygen 
consumption. Two-way analysis of variance. WT vs TG. P<0.05. Bonferroni posttests. Day, 
P<0.05; dark phase, P<0.05; light phase, P<0.05. Energy expenditure. Student’s t-test. Two 
tailed. WT vs TG. P<0.05. 
Figure 2, panel E. IPGTT. Two-way repeated measures analysis of variance, WT vs TG. P<0.05. 
Student’s t-test. Two tailed. WT-AUC vs TG-AUC, P<0.05. ITT. Two-way repeated measures 
analysis of variance, WT vs TG. P>0.05. Student’s t-test. Two tailed. WT-AUC vs TG-AUC, 
P>0.05. 
Figure 2, panel F. Two-way analysis of variance. DMSO vs FSK. P<0.05. Bonferroni posttests. 
WT, P<0.05. TG, P>0.05. 
Figure 2, panel G. Student’s t-test. Two tailed. WT vs TG. Glucose infusion rate, P<0.05. 
Hepatic glucose production. Two-way analysis of variance. WT vs TG. P<0.05. Bonferroni 
posttests. Basal, P<0.05. Clamp, P<0.05. 
Figure 2, panel H. Student’s t-test. Two tailed. WT vs TG. Relative AKT phosphorylation, liver, 
P<0.05; WAT, P>0.05; muscle, P>0.05. 
Figure 2, panel I. Two-way analysis of variance. WT vs TG. P<0.05. Bonferroni posttests. 
G6pase, P<0.05. Pepck, P<0.05. 
Figure 3, panel B. Student’s t-test. Two tailed. WT vs TG. Hepatic triglycerides, P<0.05. Hepatic 
cholesterol, P>0.05. 
Figure 3, panel C. Two-way analysis of variance. WT vs TG. P>0.05.  
Figure 3, panel D. Two-way analysis of variance. WT vs TG. P>0.05.  
Figure 3, panel E. Student’s t-test. Two tailed. WT vs TG. P<0.05. 
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Figure 3, panel F. Liver. Two-way analysis of variance. WT vs TG. P<0.05. Bonferroni posttests. 
Tnfα, P<0.05; Mcp-1, P<0.05. WAT. Two-way analysis of variance. WT vs TG. P>0.05. MUS. 
Two-way analysis of variance. WT vs TG. P>0.05. 
Figure 3, panel G right. Student’s t-test. Two tailed. WT vs TG. P>0.05. 
Figure 4, panel A. Two-way analysis of variance. WT vs TG. P>0.05. 
Figure 4, panel B. Student’s t-test. Two tailed. WT vs TG. P>0.05. 
Figure 4, panel C. Two-way repeated measures analysis of variance, WT vs TG. P>0.05. 
Student’s t-test. Two tailed. WT-AUC vs TG-AUC. P>0.05. 
Figure 4, panel D. Two-way analysis of variance. WT vs TG. P>0.05.  
Figure 4, panel E. Two-way analysis of variance. WT vs TG. P>0.05.  
Figure 5, panel A right. Two-way analysis of variance. WT vs TG. P<0.05. Bonferroni posttests. 
E1, P<0.05. E1S, P<0.05. 
Figure 5, panel B. Two-way analysis of variance. WT vs TG. P<0.05. Bonferroni posttests. VEH, 
P<0.05. ES, P<0.05. 
Figure 5, panel C. Student’s t-test. Two tailed. WT vs TG. Serum estradiol, P>0.05. Estrous 
cycle, P>0.05. 
Figure 5, panel D. Two-way analysis of variance. WT vs TG. P>0.05.  
Figure 5, panel E. Two-way repeated measures analysis of variance, WT vs TG. P>0.05. 
Student’s t-test. Two tailed. WT vs TG.P>0.05. 
Figure 5, panel F. Two-way analysis of variance. WT vs TG, Left, P>0.05. Middle, P>0.05. 
Right. Student’s t-test. Two tailed. WT vs TG.P>0.05. 
Figure 6, panel A. Student’s t-test. Two tailed. ob/ob vs obS. Body weight, P>0.05. Fat mass, 
P>0.05. Lean mass, P<0.05. 
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Figure 6, panel B. IPGTT. Two-way repeated measures analysis of variance, ob/ob vs obS. 
P<0.05. Student’s t-test. Two tailed. ob/ob-AUC vs obS-AUC. P<0.05. ITT. Two-way repeated 
measures analysis of variance, ob/ob vs obS. P>0.05. Student’s t-test. Two tailed. ob/ob-AUC vs 
obS-AUC. P>0.05. 
Figure 6, panel C. Two-way analysis of variance. ob/ob vs obS. P>0.05. Bonferroni posttests. 
G6pase, P<0.05. Pepck, P>0.05. 
Figure 6, panel D. Two-way analysis of variance. ob/ob vs obS. P<0.05. Bonferroni posttests. 
Tnfα, P<0.05. Mcp1, P<0.05. Il1, P<0.05. 
Figure 6, panel E. Student’s t-test. Two tailed. ob/ob vs obS. Triglycerides, P<0.05. Cholesterol, 
P>0.05. 
Figure 6, panel F. Two-way analysis of variance. ob/ob vs obS. Left. P>0.05. Right. P>0.05. 
Figure 6, panel G. Student’s t-test. Two tailed. ob/ob vs obS. P>0.05. 
Figure 7, panel A. Two-way repeated measures analysis of variance. VEH vs ES. P<0.05. 
Bonferroni posttests. Day 1, P>0.05. Day 3, P<0.05. Day 5, P<0.05. Day 7, P<0.05. 
Figure 7, panel B. IPGTT. Two-way repeated measures analysis of variance. VEH vs ES. P<0.05. 
Student’s t-test. Two tailed. VEH-AUC vs ES-AUC, P<0.05. ITT, Two-way repeated measures 
analysis of variance. VEH vs ES. P>0.05. Student’s t-test. Two tailed. VEH-AUC vs ES-AUC, 
P>0.05. 
Figure 7, panel C. IPGTT. Two-way repeated measures analysis of variance. VEH vs ES. P<0.05. 
Student’s t-test. Two tailed. VEH-AUC vs ES-AUC, P<0.05. ITT, Two-way repeated measures 
analysis of variance. VEH vs ES. P<0.05. Student’s t-test. Two tailed. VEH-AUC vs ES-AUC, 
P<0.05. 
Figure 8, panel A. Student’s t-test. Two tailed. WT vs TG, P>0.05. 
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Figure 8, panel B. Two-way analysis of variance. WT vs TG. P>0.05. Bonferroni posttests. Body 
weight, P>0.05. Lean mass, P<0.05. Fat mass, P<0.05.  
Figure 8, panel C. Student’s t-test. Two tailed. WT vs TG. Energy expenditure, P<0.05. Oxygen 
consumption, P<0.05. 
Figure 8, panel D. Two-way repeated measures analysis of variance. WT vs TG. P<0.05. 
Student’s t-test. Two tailed. WT-AUC vs TG-AUC, P<0.05. ITT, Two-way repeated measures 
analysis of variance. VEH vs ES. P>0.05. Student’s t-test. Two tailed. WT-AUC vs TG-AUC, 
P>0.05. 
Figure 8, panel E. Two-way analysis of variance. WT vs TG. Left. P>0.05.  Bonferroni posttests. 
G6pase, P<0.05. Pepck, P>0.05. Right. P<0.05. Bonferroni posttests. Tnfα, P>0.05. Mcp-1, 
P<0.05. 
Figure 8, panel F. Two-way analysis of variance. WT vs TG. P<0.05. Bonferroni posttests. Cd68, 
P<0.05. F4/80, P<0.05. Tnfα, P<0.05. Mip1α, P<0.05.  Il1, P<0.05.  Mcp-1, P<0.05. 
Figure 8, panel G. Left. Two-way analysis of variance. WT vs TG. P<0.05. Bonferroni posttests. 
Mcp-1, P<0.05. F4/80, P>0.05. Cd68, P<0.05.  Middle. Student’s t-test. Two tailed. WT vs TG, 
P<0.05. Right. Two-way analysis of variance. WT vs TG. P<0.05. Bonferroni posttests. Pgc1α, 
P<0.05.  Pparα, P<0.05. Mcad, P<0.05. Ucp3, P<0.05. 
Figure 8, panel H. Student’s t-test. Two tailed. Left, WT vs TG. P>0.05. Right, ob/ob vs obS. 
P>0.05. 
Figure 9, panel A. Student’s t-test. Two tailed. Control vs Alcoholic hepatitis. P<0.05. 
Figure 9, panel B. Two-way analysis of variance. Control vs Alcoholic hepatitis. P<0.05. 
Bonferroni posttests. CYP3A4, P<0.05. CYP1A2, P<0.05. EST, P<0.05. 
Figure 9, panel C. Student’s t-test. Two tailed. Control vs Alcoholic hepatitis. IL-8, P<0.05. 
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Figure 9, panel D. Regression between the mRNA expression of STS and that of IL-8. r2=0.5390, 
P<0.01. y=0.3151x+1.045 
Table 2. Fisher's exact test. Age vs STS expression. P>0.05. Gender vs STS expression. P>0.05. 
Cirrhosis vs STS expression. P<0.05. 
Figure 10, panel A. Student’s t-test. Two tailed. VEH vs LPS. P<0.05. 
Figure 10, panel B. Student’s t-test. Two tailed. VEH vs LPS. P>0.05. 
Figure 10, panel C. Student’s t-test. Two tailed. VEH vs LPS. CYP3A4, P<0.05. CYP2A1, 
P<0.05. EST, P<0.05. 
Figure 10, panel E. Student’s t-test. Two tailed. VEH vs LPS.P<0.05. 
Figure 10, panel F. One-way analysis of variance. P<0.05. Bonferroni's multiple comparison test. 
VEH vs TNFα, P<0.05. VEH vs PMA. P<0.05. 
Figure 11, panel C. Two-way analysis of variance. Vector vs p65. P<0.05. Bonferroni posttests. 
Student’s t-test. Two tailed. Vector vs p65. Promoter 1, P<0.05. Promoter 2, P>0.05. Promoter 3, 
P>0.05. Promoter 4, P>0.05. Promoter 5, P<0.05. Promoter 6, P>0.05. 
Figure 11, panel D. Two-way analysis of variance. VEH vs TNFα. P<0.05. Bonferroni posttests. 
STS promoter, NF-κB1, P<0.05; NF-κB2, P<0.05; NF-κB3, P>0.05. IL-8 promoter. Student’s t-
test. Two tailed. VEH vs TNFα. P<0.05. 
Figure 12, panel A. Two-way analysis of variance. VEH vs PMA. P<0.05. Bonferroni posttests. 
Control siRNA, P<0.05. siSTS, P>0.05. 
Figure 12, panel B. Student’s t-test. Two tailed. Control siRNA vs siSTS. P<0.05. 
Figure 12, panel C. Student’s t-test. Two tailed. VEH vs PMA. P<0.05. One-way analysis of 
variance. P<0.05. Bonferroni's multiple comparison test. VEH vs ES. P<0.05. ES vs ES+PMA. 
P<0.05. 
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Figure 12, panel D. One-way analysis of variance. P<0.05. Bonferroni's multiple comparison test. 
VEH vs PMA. P<0.05. PMA vs PMA+PDTC. P<0.05. PMA vs PMA+STX. P<0.05. PMA vs 
PMA+ICI. P<0.05. 
Figure 12, panel E. Student’s t-test. Two tailed. VEH vs LPS. TFF1, P<0.05. XBP1, P<0.05. 
Figure 12, panel F. Two-way analysis of variance. Treatment. P<0.05. Bonferroni posttests. 
Control siRNA-VEH vs Control siRNA-TNFα. TFF1, P<0.05. XBP1, P<0.05. Control siRNA-
TNFα vs siSTS-TNFα. TFF1, P<0.05. XBP1, P<0.05. 
Figure 13, panel A. One-way analysis of variance. P<0.05. Bonferroni's multiple comparison test. 
VEH vs PMA. P<0.05. PMA vs PMA+ES. P<0.05. PMA vs PMA+ES+STS. P<0.05. PMA vs 
PMA+E2. P<0.05. 
Figure 13, panel B. Student’s t-test. Two tailed. VEH vs PMA, P<0.05. PMA vs PMA+STX, 
P<0.05. PMA vs PMA+ICI, P<0.05. 
Figure 13, panel C. Two-way analysis of variance. Treatment. P<0.05. Bonferroni posttests. 
TNFα vs TNFα+STX. IL-8, P<0.05. MCP-1, P<0.05. 
Figure 13, panel D. Two-way analysis of variance. Treatment. P<0.05. Bonferroni posttests. 
Control siRNA-TNFα vs siSTS-TNFα. IL-8, P<0.05. VCAM, P<0.05. 
Figure 13, panel E. IL-8. One-way analysis of variance. P<0.05. Bonferroni's multiple 
comparison test. TNFα vs TNFα+ICI, P<0.05. MCP-1. One-way analysis of variance. 
Bonferroni's multiple comparison test. TNFα vs TNFα+ICI, P<0.05. 
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